EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Please find below the online abstract Poster Walks of the last EAHP Congresses.
Please select the desired annual Congress to view the posters presented in the different topic categories.
| PDF Document | Poster Title | Poster Number |
|---|---|---|
 | EXTEMPORANEOUS FLUCYTOSINE 15,5% INTRAVAGINAL GEL TO TREAT REFRACTORY CANDIDA GLABRATA VULVOVAGINTIS – CASE REPORT | NP-001 |
| MEDICATION SAFETY: STRATEGIES & OPPORTUNITIES IN CLINICAL PHARMACY PRACTICE | NP-002 | |
| PATIENT MEDICINE GUIDES SUPPORT SAFE MEDICATION TREATMENT AND DISCHARGE FROM THE HOSPITAL IN PAEDIATRIC SPECIALISED MEDICAL CARE | NP-003 |
| PALL-OLU.DE: A NEW DATABASE ON THE OFF-LABEL USE OF DRUGS IN PALLIATIVE MEDICINE | NP-004 |
| UNAUTHORISED MEDICATION USE IN ESTONIAN HOSPITALS | NP-005 |
| DRUGHOST, THE FIRST DATABASE OF UNAVAILABLE DRUGS IN EUROPE—AN ITALIAN MODEL: DATA ONE YEAR AFTER THE START OF THE PLATFORM | NP-006 |
| VALIDATION OF ANTIMICROBIAL DEFINED DAILY DOSE (DDD) FOR THE PAEDIATRIC POPULATION: FINAL RESULTS OF KIDDDS PROJECT | NP-007 | |
| CASE REPORT : SINGLE-USE CRANIAL DRILLS, HIGH-RISK DEVICES! | NP-008 |
| BARRIERS AND FACILITATORS TO PHARMACY PROFESSIONALS’ SPECIALIST PUBLIC HEALTH SKILLS: A MIXED METHODS UK-WIDE PHARMACEUTICAL PUBLIC HEALTH EVIDENCE REVIEW | NP-009 | |
| COMPATIBILITY OF LOCAL ANESTHETIC AND CORTICOSTEROID MIXTURES IN TRANSFORAMINAL EPIDURAL STEROID INJECTIONS | NP-010 |
| LINEZOLID THERAPEUTIC DRUG MONITORING AMONG CRITICALLY ILL ADULT PATIENTS AFTER CARDIOVASCULAR SURGERY | NP-011 | |
| IMPROVING THE CLINICAL PHARMACIST HANDOVER PROCESS USING AN ADAPTED ISBAR COMMUNICATION TOOL WHEN TRANSFERRING PATIENTS FROM CORK UNIVERSITY MATERNITY HOSPITAL (CUMH) TO AN INTENSIVE CARE UNIT (ICU) WITHIN CORK UNIVERSITY HOSPITAL (CUH). | NP-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ANALYSIS OF THE USE OF ORAL ONCOLOGY TARGETED THERAPIES IN A REGION OF SPAIN | 1ISG-001 |
| PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE | 1ISG-002 |
| PHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE | 1ISG-002 |
| DIGITAL TRANSFORMATION OF THE HOSPITAL/TERRITORIAL PHARMACY – TELEPHARMACY NEW DIMENSION OF PATIENT CARE MODELS | 1ISG-003 |
| MULTIDISCIPLINARY MANAGEMENT OF CENTRAL VENOUS CATHETERS (CVCS) IN HEMODIALYSIS PATIENTS. | 1ISG-004 |
| ASSESSMENT OF A MANAGEMENT TOOL REGARDING MEDICAL DEVICE VIGILANCE | 1ISG-005 | |
| ECONOMIC SAVING OF THE PREPARATION OF SUBCUTANEOUS FORMULATIONS COMPARED TO INTRAVENOUS: FOCUS ON DARATUMUMAB IN THREE HEALTHCARE COMPANIES | 1ISG-006 |
| HTA ANALYSIS FOR THE INCLUSION OF ANDEXANET ALFA (AA) WITHIN THE HOSPITAL THERAPEUTIC HANDBOOK (HTH) – THE EXPERIENCE OF AN ITALIAN CENTER SPECIALIZING IN CARDIOVASCULAR DISEASES | 1ISG-007 |
| USABILITY EVALUATION OF AN INSULIN MANAGEMENT SOLUTION WITHIN AN ELECTRONIC PATIENT RECORD | 1ISG-008 | |
| PHARMACOECONOMIC ANALYSIS OF AN ALTERNATIVE DOSAGE REGIMEN FOR PALIVIZUMAB | 1ISG-009 |
| ECONOMIC IMPACT OF THE CLINICAL PHARMACIST ON THE REDUCTION OF DRUG-RELATED PROBLEMS BEFORE THE INITIATION OF AN ANTI-TUMOR TREATMENT – A PROSPECTIVE MULTICENTER TRIAL | 1ISG-010 |
| OPPORTUNITY FOR DAILY HOME-BASED MANAGEMENT OF CHRONIC PATIENTS FROM THE SAME AREA USING AN INTERPROFESSIONAL NETWORK MODEL DEVISED, SET UP AND IMPLEMENDET FOR THE COVID-19 | 1ISG-011 |
| BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS | 1ISG-012 |
| BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS | 1ISG-012 | |
| REAL-LIFE DATA OF CDK4/6 INHIBITORS PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER: EFFECTIVENESS EVALUATION | 1ISG-013 |
| SUSTAINABLE HEALTHCARE: AN EXAMPLE OF PHARMACEUTICAL INTERVENTION | 1ISG-014 |
| ASSESSMENT OF PREPARATORY STAFF’S KNOWLEDGE OF CARCINOGENIC, MUTAGENIC AND REPROTOXIC (CMR) RISKS | 1ISG-015 |
| OCRELIZUMAB FOR THE TREATMENT OF RECAPTING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN NATIONAL HEALTH SYSTEM: A COST EFFECTIVENESS ANALYSIS | 1ISG-016 |
| THE THREE HORIZONS METHOD AS A TOOL FOR DEFINING THE HOSPITAL PHARMACY RESIDENT OF THE FUTURE(HPRF) | 1ISG-017 |
| TEN-YEAR DRUG SURVIVAL ANALYSIS IN MODERATE TO SEVERE PLAQUE PSORIASIS FIRST-LINE TREATMENT | 1ISG-018 | |
| DO ALL SURGICAL SPECIALTIES HAVE AN IDENTICAL CARBON FOOTPRINT WHITIN AN AMBULATORY UNIT ? | 1ISG-019 |
| DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT | 1ISG-020 |
| DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT | 1ISG-020 | |
| 1 YEAR-REVIEW OF THE EKOSONIC® ENDOVASCULAR SYSTEM (BOSTON SCIENTIFIC) IN THE MANAGEMENT OF PULMONARY EMBOLISM IN AN INTERVENTIONAL CARDIOLOGY DEPARTMENT | 1ISG-021 |
| HOSPITAL PHARMACISTS’ PERCEPTIONS OF THEIR PROFESSION IN TWO EUROPEAN COUNTRIES | 1ISG-022 |
| ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL | 1ISG-023 |
| ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL | 1ISG-023 | |
| SINGLE-USE MEDICAL DEVICES IN THE TREATMENT OF CHRONIC DISEASES: WHAT IS THE ENVIRONMENTAL IMPACT? | 1ISG-024 |
| ANALYSIS OF THE COMPLEXITY OF THE CLINICAL TRIALS CARRIED OUT IN A THIRD-LEVEL HOSPITAL | 1ISG-025 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CLINICAL IMPACT AND COST SAVINGS OF AN OUTPATIENT ANTIMICROBIAL THERAPY PROGRAMME: A FOCUS ON SELF-ADMINISTRATION | 2SPD-001 |
| EVALUATION OF THE EFFECTIVENESS AND RELATED COST OF ONCOLOGY DRUGS USED IN SPECIAL SITUATIONS, IN A THIRD-LEVEL UNIVERSITY HOSPITAL | 2SPD-002 |
| PROPER MANAGEMENT AND ECONOMIC BURDEN OF UNUSED MEDICATIONS DISPOSAL IN A SUSTAINABLE LATIN AMERICAN HOSPITAL: A RETROSPECTIVE STUDY | 2SPD-003 | |
| BUDGETARY IMPACT OF THE INTRODUCTION OF CABOTEGRAVIR PLUS RILPIVIRINE LONG-ACTING IN A THIRD LEVEL HOSPITAL | 2SPD-004 | |
| ALTERNATIVE TO THE TREATMENT OF POOR GRAFT FUNCTION AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: ELTROMBOPAG | 2SPD-005 |
| IMPACT AND CONSEQUENCES OF THE USE OF HUMAN POLYVALENT IMMUNOGLOBULIN DURING THE COVID-19 PANDEMIC (2019-2022) | 2SPD-006 | |
| USE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL | 2SPD-007 |
| SWITCHING TO A BIOSIMILAR ADALIMUMAB IN DUTCH UNIVERSITY MEDICAL CENTERS: IT IS NOT THAT HARD! | 2SPD-008 |
| A FIVE-YEAR RETROSPECTIVE REPORT ON COMPREHENSIVE MEDICINE PROCUREMENT WITHIN A PUBLIC GROUP PROCUREMENT ORGANISATION | 2SPD-009 | |
| IDENTIFYING AND QUANTIFYING DRUG-RELATED WASTE IN A HEALTHCARE ESTABLISHMENT | 2SPD-010 |
| AVAILABILITY OF LIQUID ANTIMICROBIALS – A NATIONAL ANALYSIS OF THE CURRENT SUPPLY SITUATION | 2SPD-011 |
| APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE AUTOMATED DISPENSING CABINETS’ DRUG STOCK MANAGEMENT PROCESSES | 2SPD-012 |
| A COMPARATIVE LIFE CYCLE ASSESSMENT OF DIFFERENT PACKAGING OPTIONS FOR ALBUMIN DISTRIBUTION | 2SPD-013 |
| ECO-CONSCIOUS HEALTHCARE PRODUCTS SUPPLY: INVESTIGATING THE EFFECTS OF FEWER ORDERS | 2SPD-014 |
| INTEGRATED HEALTHCARE LOGISTICS: KANBAN SOLUTION FOR MANAGEMENT OF DIALYSIS WAREHOUSES PILOT CASE | 2SPD-015 | |
| DATA-DRIVEN SELECTION OF A MEDICATION MANAGEMENT MODEL IN HOSPITALISATION WARDS | 2SPD-016 |
| RISK IDENTIFICATION IN ANTIDOTE AND EMERGENCY PREPAREDNESS | 2SPD-017 | |
| IMPACT OF INHALERS ON CO2 EMISSION IN A HEALTH AREA | 2SPD-018 |
| TOWARDS A SUSTAINABLE OPERATING ROOM : FEEDBACK ON ACTIONS CARRIED OUT AROUND MEDICAL DEVICES | 2SPD-019 |
| DESIGN AND EVALUATION OF AN INNOVATIVE AIRBORNE TRANSPORT SYSTEM FOR BLOOD-DERIVED DRUGS UNDER EMERGENCY CONDITIONS | 2SPD-020 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| TOPICAL COMPOUNDED CLINDAMYCIN SOLUTION MADE FROM ORAL DOSAGE FORMS, CONTROL AND STABILITY STUDY | 3PC-001 |
| STABILITY OF TENECTEPLASE SYRINGES AFTER FRACTIONATION | 3PC-002 | |
| SUITABILITY OF ELASTOMERIC PUMPS FOR DRUG STORAGE | 3PC-003 |
| DRUG WASTE OF READY-TO-ADMINISTER SYRINGES IN THE INTENSIVE CARE UNIT: ASEPTICALLY PREPARED SYRINGES VERSUS PREFILLED STERILISED SRYINGES | 3PC-004 |
| PREPARATION OF EPICUTANEOUS TESTS WITH MINOXIDIL AT 2% AND 5%. | 3PC-005 |
| STABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS | 3PC-006 |
| CONTAINMENT PERFORMANCE ASSESSMENT OF CHEMFORT® (ONGUARD®2) CLOSED SYSTEM TRANSFER DEVICE ACCORDING TO 2016 DRAFT NIOSH PROTOCOL AT FIRST AND TENTH ACTIVATIONS END OF SHELF LIFE. | 3PC-007 |
| STABILITY OF PARENTERAL NUTRITION ADMIXTURES: FOCUS ON PRECIPITATION. | 3PC-008 |
| THE EFFECT OF ACCELERATED LIGHT (STRESS) AND NATURAL SUNLIGHT EXPOSURES ON CETUXIMAB (ERBITUX®): EVALUATION OF AGGREGATE FORMATION AND FUNCTIONALITY | 3PC-009 |
| DEVELOPMENT OF A STABLE PARENTERAL SOLUTION OF TOPIRAMATE FOR EMERGENCY TREATMENT OF STATUS EPILEPTICUS | 3PC-010 |
| MUCOSECTOMY : FEASIBILITY STUDY OF THE AUTOMATED PREPARATION OF A STERILE SOLUTION OF 5/10% FRUCTOSE GLYCEROL. | 3PC-011 |
| CONTENT UNIFORMITY OF SODIUM BENZOATE CAPSULES: VALIDATION OF A METHOD USING QCPREP® | 3PC-012 |
| RADIOPHARMACEUTICAL SINGLE-VIAL COLD KIT FORMULATION OF FAPI-04, AN EXPERIMENTAL VECTOR FOR GALLIUM-68 PET IMAGING IN ONCOLOGY | 3PC-013 |
| PHYSICOCHEMICAL STABILITY OF BEVACIZUMAB 25 MG/ML CONCENTRATE (VEGZELMA®) IN ORIGINAL GLASS VIALS AFTER FIRST OPENING | 3PC-014 |
| MICROBIOLOGICAL PERFORMANCE QUALIFICATION OF THE ROBOTIC SYSTEMS APOTECASYRINGE AND APOTECAUNIT | 3PC-015 |
| PHYSICOCHEMICAL STABILITY OF MOXIFLOXACIN 1 MG/0,2 ML SYRINGES FOR INTRACAMERAL ADMINISTRATION | 3PC-016 |
| ELABORATION OF DEFEROXAMINE EMULSION 0.5% FOR HYPERPIGMENTATION DUE TO INTRAVENOUS IRON EXTRAVASATION | 3PC-017 |
| GLASS AMPOULE HANDLING PRACTICES IN DUTCH HEALTHCARE: A COMPREHENSIVE ASSESSMENT | 3PC-018 |
| DEVELOPMENT A TOPICAL EMULSION FOR THE TREATMENT OF THIRD-DEGREE BURN PATIENTS CANDIDATES FOR SKIN GRAFT | 3PC-019 |
| PREVENTION OF INFECTIOUS RISK IN PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHIBITORS (ANTI-TNFΑ) | 3PC-020 |
| FORMULATION OF VORICONAZOLE OVULES AND EFFICACY IN VULVOVAGINAL CANDIDIASIS BY CANDIDA GLABRATA: A CASE REPORT. | 3PC-021 |
| DESIGN AND STABILITY STUDY OF AN ISONIAZID AND PYRIDOXINE ORAL LIQUID FORMULATION | 3PC-022 |
| NEW ACTIVITIES WITHIN A CLINICAL TRIAL MANAGEMENT UNIT: WHAT NEW RISKS FOR THE STAFF? | 3PC-023 |
| IMPLEMENTATION OF A STRATEGY TO OVERCOME THE POTENTIAL TOXIC EFFECTS OF PROPYLENE GLYCOL IN NEONATES | 3PC-024 |
| STABILITY STUDY OF STANDARDISED FLUID THERAPY PREPARED BY THE PHARMACY DEPARTMENT TO TREAT PEDIATRIC DIABETIC KETOACIDOSIS | 3PC-025 |
| COST SAVINGS ASSOCIATED WITH ROMIPLOSTIM REPACKAGING IN PATTIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA | 3PC-026 |
| USE OF AUTOMATED COMPOUNDING DEVICES IN PEDIATRIC PARENTERAL NUTRITION: A GOOD WAY TO ENSURE SAFETY | 3PC-027 | |
| FOR A MORE ECONOMICAL AND ECOLOGICAL CENTRAL STERILE SERVICES DEPARTMENT (CSSD) : BACK TO THE CONTAINER | 3PC-028 | |
| PH MEASUREMENT: NOT AS SIMPLE AS WE THINK? A CASE OF SODIUM PERCHLORATE INJECTIONS | 3PC-029 |
| STABILITY STUDY OF AN EPIDURAL ANALGESIC CONCENTRATE FOR INFUSION USED DURING CHILDBIRTH | 3PC-030 |
| USABILITY OF SEMI-SOLID EXTRUSION 3D PRINTING IN HOSPITAL PHARMACY SETTINGS TO PRODUCE PERSONALISED ORAL MEDICATIONS FOR PEDIATRIC PATIENTS | 3PC-031 |
| OPTIMIZATION OF AN INSULIN 1 IU/ML EYE DROP FORMULATION FOR THE TREATMENT OF CORNEAL ULCERS | 3PC-032 |
| KIRO ISOLATOR®: A NEW, RELIABLE, ROBOTIC DEVICE FOR THE COMPOUNDING OF INJECTABLE ANTICANCER DRUGS | 3PC-033 | |
| FORMULATION OF KETAMINE 1% AND AMITRIPTYLINE 1% GEL IN PRURITIC EPIDERMOLYSIS BULLOSA: A CASE REPORT | 3PC-034 |
| PATCH TESTS WITH HAZARDOUS DRUGS: IS IT POSSIBLE TO ENSURE SAFETY DURING PRODUCTION? | 3PC-035 |
| RISK ANALYSIS OF THE PHARMACEUTICAL CIRCUIT FOR INJECTABLE CHEMOTHERAPIES AFTER IMPLEMENTATION OF DRUGLOG ®. | 3PC-036 |
| ALUMINIUM IN PEDIATRIC PARENTERAL NUTRITION: ARE MULTICHAMBER-BAGS THE SAFER CHOICE? | 3PC-037 | |
| AUTOLOGOUS SERUM EYE DROPS PREPARATION: APPROACH TO THE FILTRATION STEP IMPACT ON THE CONCENTRATION OF ACTIVE MOLECULES | 3PC-038 |
| EARLY DE-RISKING OF THE STABILITY OF A PERSONALISED, STERILE BACTERIOPHAGE SUSPENSION ON THE BASIS OF ADVANCED KINETIC MODELING | 3PC-039 | |
| RADIOCHEMICAL PURITY DETERMINATION OF 177LU-PSMA-617: DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYTICAL METHOD | 3PC-040 |
| PUBLIC PRODUCTION OF THERAPEUTIC BACTERIOPHAGES | 3PC-041 | |
| STERILE AND NON-STERILE COMPOUNDING: RISK ANALYSIS AND IMPROVEMENT MEASURES | 3PC-042 |
| INTRAVITREAL PREPARATION OF LIPOSOMAL B AMPHOTERICIN: FROM FORMULATION STUDY TO PREPARATION | 3PC-043 |
| A PHYSICO-CHEMICAL STABILITY STUDY OF VANCOMYCIN EYE DROP AFTER DIFFERENT THAWING TIMES | 3PC-044 | |
| RETROSPECTIVE STUDY OVER 6 YEARS OF THE TREND IN FUNGAL CONTAMINATION OF CONTROLLED ATMOSPHERE AREAS WITHIN A CELL THERAPY UNIT. | 3PC-045 |
| RISK OF PERSONNEL EXPOSURE TO HAZARDOUS DRUGS IN ROBOTIC COMPOUNDING | 3PC-046 |
| PEDIATRIC IV ANTIFUNGAL ADMIXTURES: CENTRALISATION’S ECONOMIC CONSEQUENCES | 3PC-047 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| COMPARATIVE ANALYSIS OF TWO PHARMACOKINETIC PROGRAMMES FOR LITHIUM ADJUSTMENT | 4CPS-001 |
| PHARMACEUTICAL CARE IN POSTOPERATIVE PAIN MANAGEMENT AT ADMISSION AND DISCHARGE | 4CPS-002 | |
| EVALUATION OF CLINICAL VARIABLES IMPACT ON ENOXAPARIN DOSING AND ANTIXA CONCENTRATION | 4CPS-003 |
| IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS | 4CPS-004 |
| DRUG PERSISTENCE OF JAK INHIBITORS COMPARED TO BIOLOGIC DRUGS IN REAL-WORLD PRACTICE IN PATIENTS WITH RHEUMATOID ARTHRITIS | 4CPS-005 |
| ADHERENCE TO NEBULIZED ANTIBIOTICS IN CYSTIC FIBROSIS PATIENTS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR | 4CPS-006 |
| ADALIMUMAB IN THE TREATMENT OF RECALCITRANT SWEET SYNDROME: A CASE REPORT | 4CPS-007 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO ANTITHROMBOTIC DRUGS IN EMERGENCY DEPARTMENT | 4CPS-008 |
| NEONATAL DIAGNOSIS AND TREATMENT OF STIFF BABY SYNDROME: A CASE REPORT | 4CPS-009 |
| CAN ERENUMAB IMPROVE QUALITY OF LIFE PERCEIVED BY PATIENTS? | 4CPS-010 | |
| REAL-WORLD EFFECTIVENESS AND SURVIVAL OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIASIC ARTRHITIS: MULTICENTER ANALYSIS IN DAILY CLINICAL PRACTICE BY THE VALENCIAN COMMUNITY PSORIASIS GROUP. | 4CPS-011 |
| IMPROVING PARENTAL MEDICATION LITERACY BY PHARMACIST-LED DISCHARGE COUNSELLING IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | 4CPS-012 |
| INTRAVENOUS LEVETIRACETAM SUPPLETION DURING HAEMODIALYSIS PRESERVED STABLE THERAPEUTIC SERUM CONCENTRATIONS: A CASE REPORT | 4CPS-013 |
| REAL WORLD DATA ON THE USE OF PCSK9 INHIBITOR TREATMENTS IN HYPERCHOLESTEROLEMIA | 4CPS-014 |
| ASSESSMENT OF IN-HOSPITAL ANTIBIOTICS CONSUMPTION PATTERN ACCORDING TO THE WHO AWARE CLASSIFICATION IN A LOCAL HEALTH AUTHORITY | 4CPS-015 |
| EXPERIENCES, VIEWS AND ATTITUDES OF HOSPITAL NURSING STAFF TOWARDS THE IMPLEMENTATION OF THE UNIT DOSE DISPENSING SYSTEM FOR INPATIENTS: A QUALITATIVE INTERVIEW STUDY | 4CPS-016 |
| COMPARATIVE STUDY BETWEEN TIXAGEVIMAB/CILGAVIMAB AND SOTROVIMAB IN PATIENTS WITH COVID-19: A MONOCENTRIC EXPERIENCE AT UNIVERSITY HOSPITAL | 4CPS-017 |
| SWITCHING BETWEEN CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN THE PROPHYLAXIS OF MIGRAINE | 4CPS-018 |
| DIFFERENCES IN MEROPENEM DOSE ADJUSTMENT WITH CALCULATION OF GLOMERULAR FILTRATION RATE THROUGH DIFFERENT FORMULAS. | 4CPS-019 |
| EVALUATION OF THE EFFECTIVENESS OF MONOCLONAL ANTIBODIES AGAINST MIGRAINE HEADACHE | 4CPS-020 |
| PERFORMANCE OF MULTIPLE TRIGGER TOOLS IN IDENTIFYING MEDICATION-RELATED HOSPITAL READMISSIONS | 4CPS-021 |
| THE EFFECT OF DIGITAL CLINICAL DECISION SUPPORT ON PHARMACOTHERAPY IN HOSPITALISED (MORBIDLY) OBESE PATIENTS: A PROSPECTIVE INTERVENTION STUDY | 4CPS-022 | |
| OPTIMISING BIOLOGIC THERAPY IN SEVERE UNCONTROLLED ASTHMA PATIENTS ON OMALIZUMAB TREATMENT | 4CPS-023 |
| ANALYSIS OF POLYMEDICATION AND ADEQUACY TREATMENT RECOMMENDATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS IN A TERTIARY LEVEL HOSPITAL. | 4CPS-024 |
| MANAGEMENT OF COVID-19 WITH NIRMATRELVIR/RITONAVIR AND TACROLIMUS MONITORING IN RENAL TRANSPLANTATION: A CASE REPORT | 4CPS-025 |
| ACCEPTABILITY AND WILLINGNESS TO SWITCH ANTIRETROVIRAL TREATMENT IN PATIENTS WITH LONG-ACTING INJECTABLE THERAPY CRITERIA. | 4CPS-026 |
| ANALYSIS OF CARDIOVASCULAR RISK ASSOCIATED WITH IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE TREATMENT IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA | 4CPS-027 |
| ANALYSIS OF INTERACTIONS DETECTED IN THE CONCOMITANT USE OF ANTINEOPLASTIC AGENTS AND PHYTOTHERAPY IN ONCOHEMATOLOGY PRACTICE AND INTERVENTIONS CARRIED OUT. | 4CPS-028 |
| USE OF TOPICAL 1% CIDOFOVIR ON SKIN LESIONS IN A PATIENT WITH MONKEYPOX | 4CPS-029 |
| ANALYSIS OF ADHERENCE TO GROWTH HORMONE TREATMENT IN PAEDIATRIC PATIENTS. | 4CPS-030 |
| A POPULATION PHARMACOKINETIC MODEL OF VEDOLIZUMAB IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PRELIMINARY ANALYSIS | 4CPS-031 | |
| PHARMACEUTICAL INTERVENTIONS FOR MEDICATION RECONCILIATION IN COMPLEX CHRONICALLY ILL PATIENTS | 4CPS-032 |
| REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF SELECTIVE CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS UTILISATION IN METASTATIC BREAST CANCER – REVEAL STUDY | 4CPS-033 |
| REAL-WORLD SAFETY AND TOLERABILITY IN PATIENTS TREATED WITH ABEMACICLIB AND ENDOCRINE THERAPY: A RETROSPECTIVE OBSERVATIONAL STUDY | 4CPS-034 |
| IMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAMME (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALISED WITH COMMUNITYACQUIRED PNEUMONIA (CAP): RETROSPECTIVE OBSERVATIONAL BEFORE-AFTER STUDY | 4CPS-035 |
| EVALUATION OF THE DIAGNOSIS AND ANTIBIOTIC PRESCRIPTION PATTERN IN PATIENTS HOSPITALISED WITH URINARY TRACT INFECTIONS (UTIS) | 4CPS-036 |
| INTEGRATION OF THE PHARMACIST IN THE MULTIDISCIPLINARY COMMITTEE OF URO ONCOLOGICAL PATHOLOGY | 4CPS-037 |
| CASE REPORT ON AUTONOMIC NEUROPATHY INDUCED BY BORTEZOMIB | 4CPS-038 |
| DRUG-RELATED PROBLEMS AT HOSPITAL ADMISSION IN ELDERLY PATIENTS WITH CARDIOVASCULAR DISEASES | 4CPS-039 | |
| ADHERENCE TO GUIDELINES AND PRESCRIBING TRENDS OF STATINS IN PATIENTS WITH ACUTE CORONARY SYNDROME | 4CPS-040 |
| SILENCE SPEAKS LOUDER THAN WORDS: OMISSION OF PRESCRIPTION IN THE EMERGENCY ROOM | 4CPS-041 | |
| OVERDOSE OF DARBEPOETIN IN PATIENTS WITH CHRONIC KIDNEY FAILURE. ROOM FOR IMPROVEMENT WITH PHARMACIST INTERVENTIONS | 4CPS-042 |
| EFFICACY AND SAFETY OF ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES FOR MIGRAINE PROPHYLAXIS: ONE-YEAR REAL-LIFE EXPERIENCE | 4CPS-043 |
| PRE-EXPOSURE PROPHYLAXIS DROP-OUT: FOLLOW-UP AND RELINKING THROUGH TELEPHONE CONTACT | 4CPS-044 |
| OPTIMISATION OF OMALIZUMAB FOR SEVERE ALLERGIC ASTHMA IN PEDIATRIC POPULATION | 4CPS-045 |
| EVALUATION OF HEALTH IMPACT IN INFLIXIMAB-TREATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: INCORPORATION OF PATIENT REPORTED OUTCOME MEASURES (PROMS) | 4CPS-046 |
| EVALUATION OF ANTIRESORPTIVE AGENT-RELATED OSTEONECROSIS THERAPY BY MEASURING CONCENTRATIONS OF PENICILLIN G IN JAWBONE | 4CPS-047 |
| A COMPLEX, ADHERENCE-IMPROVING PHARMACIST INTERVENTION TO REDUCE HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS | 4CPS-048 |
| TREATMENT OF ROSAI DORFMAN’S HISTIOCYTOSIS: CASE REPORT | 4CPS-049 |
| PRE-EXPOSURE PROPHYLAXIS FOR HIV INFECTION: PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS (STIS) AND ADHERENCE DURING THE PROGRAMME | 4CPS-050 |
| COST SAVING IMPACT OF BIOSIMILAR TRASTUZUMAB FOR THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN A HOSPITAL | 4CPS-051 |
| EVALUATION OF USTEKINUMAB USE IN INFLAMMATORY BOWEL DISEASES | 4CPS-052 |
| OUTCOMES OF INFRADOSED ANTIMICROBIALS PATIENTS WITH BACTEREMIA IN THE EMERGENCY DEPARTMENT | 4CPS-053 |
| NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES FOR MODERATE TO SEVERE ULCERATIVE COLITIS | 4CPS-054 |
| PHARMACOGENETICS AND ITS APPLICATIONS IN PERSONALISED MEDICINE: A SYSTEMATIC REVIEW | 4CPS-055 |
| EFFECTIVENESS AND SAFETY OF ERIBULIN THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER. | 4CPS-056 | |
| EFFECTIVENESS, SAFETY, AND PATIENT-REPORTED OUTCOME OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE | 4CPS-057 |
| ANALYSIS OF ANTIFUNGAL CONSUMPTION IN AN INTENSIVE CARE UNIT OVER 5 YEARS | 4CPS-058 |
| SEVENTEEN DRUGS, ONE SAMPLE: ANALYSING MULTIPLE ANTI-TUBERCULOSIS DRUGS SIMULTANEOUSLY USING ONE METHOD | 4CPS-059 | |
| IMPACT OF OBESITY ON VANCOMYCIN PHARMACOKINETIC PARAMETERS IN ADULT PATIENTS | 4CPS-060 |
| SAFETY AND EFFECTIVENESS OF THE OFF-LABEL USE OF CANGRELOR IN PERIOPERATIVE BRIDGING: A CASE SERIES | 4CPS-061 |
| POSITIVE IMPACT OF EXTENDING NATALIZUMAB DOSAGE INTERVAL FROM EVERY 4 WEEKS TO EVERY 6 WEEKS IN MULTIPLE SCLEROSIS PATIENTS | 4CPS-062 |
| CLINICAL PHARMACIST IN THE MULTIDISCIPLINARY TEAM IN THE INTENSIVE CARE UNIT IMPROVE THE QUALITY OF MEDICINE THROUGHOUT THE PATIENT’S HOSPITAL STAY | 4CPS-063 |
| REVIEW OF USE OF IMMUNOGLOBULINS IN TERTIARY HOSPITAL | 4CPS-064 |
| EXPERIENCE OF IMMUNOCHEMOTHERAPY VERSUS STANDARD TREATMENT IN SMALL-CELL LUNG CANCER | 4CPS-065 |
| THERAPEUTIC DRUG MONITORING OF ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE. | 4CPS-066 |
| EFFECTIVENESS AND SAFETY OF 1 IU/ML TOPICAL INSULIN TO TREAT PERSISTENT CORNEAL ULCERS | 4CPS-067 | |
| TARGET THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS TO GUARANTEE THE APPROPRIATENESS OF THE PRESCRIPTIONS IN OUR HOSPITAL | 4CPS-068 |
| OUTPATIENT SATISFACTION IN THE TELEPHARMACY PROGRAMME OF A TERTIARY HOSPITAL PHARMACY SERVICE | 4CPS-069 |
| EVALUATION OF AVOIDED COST IN CLINICAL TRIALS WITH IMMUNOTHERAPY IN LUNG CANCER | 4CPS-070 |
| ANTIBIOTIC CONSUMPTION MONITORING BY AWARE CLASSIFICATION: A SIX MONTHS ANALYSIS | 4CPS-071 |
| SETMELANOTIDE IN MONOGENIC OBESITY: A CASE REPORT | 4CPS-072 |
| ANALYSIS OF THE REASONS FOR CHANGING TREATMENT IN PATJENTS WITH MULTIPLE SCLEROSIS | 4CPS-073 |
| DRUG CLASSES COMMONLY RELATED TO MEDICATION ERRORS AT TRANSITION OF CARE | 4CPS-074 |
| A SYSTEMATIC REVIEW OF THE TARGET PHARMACOKINETIC/PHARMACODYNAMIC PARAMETERS OF ANTIBIOTICS TREATING GRAM-NEGATIVE INFECTIONS | 4CPS-075 |
| EFFECTIVENESS AND SAFETY OF DUPILUMAB AND TRALOKINUMAB IN ATOPIC DERMATITIS IN CLINICAL PRACTICE | 4CPS-076 |
| PHARMACEUTICAL INTERVENTIONS AFTER DETECTION OF NON-HANDLING MEDICATIONS IN PATIENTS WITH DYSPHAGIA | 4CPS-077 |
| QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES WITH MULTIPLE MYELOMA TREATEDS WITH DARATUMUMAB | 4CPS-078 |
| INDIRECT COMPARISON OF IL-13 INHIBITORS PLUS TOPICAL CORTICOSTEROIDS IN MODERATE TO SEVERE ATOPIC DERMATITIS | 4CPS-079 |
| METASTATIC HER2-POSITIVE BREAST CARCINOMA CASE REPORT: ANTI-HER2 TREATMENT MAINTENANCE DESPITE OLIGOPROGRESSION | 4CPS-080 |
| CONSENSUS ON INDICATORS FOR MEDICATION-RELATED READMISSIONS: A DELPHI STUDY | 4CPS-081 |
| DESCRIPTIVE STUDY OF POST-SURGERY ANALGESIC PRESCRIPTIONS | 4CPS-082 | |
| MEDICATION RECONCILIATION INTERVENTIONS IN AN EMERGENCY DEPARTMENT AT ADMISSION | 4CPS-083 |
| GENOTYPING ANALYSIS OF POLYMORPHISMS IN THE DIAHYDROPYRHYDROMIDINE DEHYDROGENASE (DPYD) GENE PRIOR TO ADMINISTRATION OF FLUOROPIRMIDINES | 4CPS-084 |
| LONG-TERM PERSISTENCE IN PSORIASIS PATIENTS WITH HIGH RESPONSE TO GUSELKUMAB: A REAL-WORLD RETROSPECTIVE STUDY. | 4CPS-085 | |
| ASSESSMENT OF THE CLINICAL RELEVANCE OF LEVETIRACETAM MONITORING | 4CPS-086 |
| ADALIMUMAB PERSISTENCE IN CLINICAL PRACTICE AT A REGIONAL HOSPITAL | 4CPS-087 |
| FOLIC ACID, FOLINIC ACID AND HEMATOTOXIC TREATMENTS: A REVIEW AT A UNIVERSITY HOSPITAL CENTRE | 4CPS-088 |
| CLINICAL PHARMACIST EFFECTIVENESS IN HOSPITALISED PATIENTS: ANALYSIS OF THE INTERVENTION RECORD IN A SECONDARY ACUTE HOSPITAL | 4CPS-089 |
| REAL-WORLD PERSISTENCE WITH FREMANEZUMAB VERSUS ERENUMAB AMONG MIGRAINE PATIENTS | 4CPS-090 |
| REAL-LIFE PERSISTENCE, EFFECTIVENESS AND SAFETY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE | 4CPS-091 |
| ANALYSIS OF ANTIBIOTICS CONSUMPTION AT AN ITALIAN CARDIOLOGY CENTRE: PHARMACOUSE PROFILE ACCORDING TO THE AWARE CLASSIFICATION | 4CPS-092 |
| ANTIBIOTIC RESISTANCE IN THE HOSPITAL CONTEXT: RETROSPECTIVE ANALYSIS OF ANTIBIOGRAMS, RESISTANCE AND SENSITIVITY PROFILES AT AN ITALIAN HEART CENTER | 4CPS-093 |
| RISK FACTORS FOR EMERGENCY DEPARTMENT RE-VISIT IN ELDERLY PATIENTS WITH GASTROINTESTINAL BLEEDING SECONDARY TO DIRECT ORAL ANTICOAGULANTS | 4CPS-094 | |
| EXPLORATORY ANALYSIS OF CARDIOVASCULAR EVENTS IN AN ASTHMATIC COHORT | 4CPS-095 | |
| USE OF COVID-19 ANTIVIRALS IN PATIENTS PREVIOUSLY TREATED WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS: EXPERIENCE OF AN ITALIAN HOSPITAL | 4CPS-096 |
| REAL-WORLD STUDY OF APALUTAMIDE TREATMENT IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN NINE HOSPITALS OF VALENCIAN COMMUNITY. | 4CPS-097 |
| EFECTIVENESS AND SAFETY OF LONG-ACTING CABOTEGRAVIR/RILPIVIRINE IN REAL-LIFE POPULATION | 4CPS-098 |
| CHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-T CELLS) AND ANTIBIOTICS : A NOT-SO-INNOCENT ASSOCIATION | 4CPS-099 |
| THE UTILITY OF EARLY PHARMACEUTICAL VALIDATION OF SELECTED HIGH-RISK DRUGS IN A HOSPITAL EMERGENCY DEPARTMENT | 4CPS-100 |
| MONITORING METABOLIC SYNDROME IN OLANZAPINE TREATED PATIENTS | 4CPS-101 |
| AMIODARONE AND LITHIUM-INDUCED THYROID DYSFUNCTION: WHO INITIATES THE PRESCRIBING CASCADE? | 4CPS-102 |
| ANALYSIS OF PNEUMONIA ASSOCIATED WITH MECHANICAL VENTILATION IN CRITICALLY ILL PATIENTS UNDERGOING SELECTIVE DIGESTIVE DECONTAMINATION. | 4CPS-103 |
| COMORBIDITY PATTERNS IN THE OLDER HIV PATIENT | 4CPS-104 |
| MEDICINES OPTIMISATION FOR PATIENTS IN A NURSING HOME | 4CPS-105 |
| AUC-SURVIVAL REANALYSIS OF TROPICS-02 TRIAL WITH SACITUZUMAB GOVITECAN FOR METASTATIC LUMINAL BREAST CANCER. | 4CPS-106 |
| ADHERENCE TO DAILY ORAL TREATMENT IN MULTIPLE SCLEROSIS | 4CPS-107 |
| CLINICAL IMPACT OF PHARMACOKINETIC MONITORING OF INFLIXIMAB AND ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE | 4CPS-108 |
| SEX-RELATED DIFFERENCES IN THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS TREATMENT | 4CPS-109 |
| SYSTEMATIC REVIEW AND E-QUESTIONNAIRE ON THE SERVICE CHARACTERISTICS, OPERATIONS AND ACTIVITIES OF CENTRES FOR MEDICINES INFORMATION (CMI) | 4CPS-110 |
| PHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS | 4CPS-111 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT | 4CPS-112 |
| THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS | 4CPS-113 |
| SUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT | 4CPS-114 |
| CHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB | 4CPS-115 |
| REAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE | 4CPS-116 |
| UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS? | 4CPS-117 |
| MEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY | 4CPS-118 |
| A REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN | 4CPS-119 |
| EFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS) | 4CPS-120 |
| OPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS | 4CPS-121 |
| ANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION | 4CPS-122 |
| SARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT | 4CPS-123 |
| MONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE | 4CPS-124 |
| PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY | 4CPS-125 |
| ADHERENCE, PERSISTENCE, AND SWITCHING MEDICATION IN PATIENTS WITH MULTIPLE SCLEROSIS INITIATING ORAL DISEASE MODIFYING THERAPIES: A RETROSPECTIVE REAL-WORLD STUDY | 4CPS-126 | |
| PERSISTENCE OF BIOLOGICAL DISEASE-MODIFYING DRUGS AND PHOSPHODIESTERASE-4- INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITHIS | 4CPS-127 |
| POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS | 4CPS-128 |
| EVALUATION OF THE BENEFIT OF CAROB FLOUR ON NINTEDANIB DIARRHEA IN THE TREATMENT OF DIFFUSE INTERSTITIAL LUNG DISEASE | 4CPS-129 |
| RISK OF HYPOKALAEMIA IN HOSPITALIZED PATIENTS ASSOCIATED WITH THE COMBINATION OF DIURETICS | 4CPS-130 |
| UTILIZATION AND SAFETY PROFILE OF UPADACITINIB IN A TERTIARY HOSPITAL | 4CPS-131 | |
| RIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION | 4CPS-132 |
| EFFECTIVENESS AND SAFETY OF ANTI IL-5 DRUGS BENRALIZUMAB AND MEPOLIZUMAB IN SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA PATIENTS | 4CPS-133 |
| REAL WORLD EVIDENCE OF CEFIDEROCOL IN CLINICAL PRACTICE | 4CPS-134 | |
| EVALUATION AND MANAGEMENT OF CONSTIPATION IN THE CRITICALLY ILL PATIENT | 4CPS-135 |
| ANALYSIS OF THE SITUATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES BEFORE AND AFTER THE COVID-19 PANDEMIC | 4CPS-136 |
| CEFIDEROCOL: UTILIZATION PROFILE IN THE TREATMENT OF MULTIDRUG-RESISTANT BACTERIA, A RETROSPECTIVE OVERVIEW. | 4CPS-137 |
| CEFIDEROCOL: EFFECTIVENESS AND MORTALITY OF MULTIDRUG-RESISTANT BACTERIA INFECTIONS, A RETROSPECTIVE OVERVIEW. | 4CPS-138 |
| VORICONAZOLE SERUM CONCENTRATIONS MONITORING | 4CPS-139 |
| EXPERIENCE OF USING PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN A TERTIARY HOSPITAL | 4CPS-140 |
| REAL-LIFE IMPACT OF INCLUDING MONTELUKAST AS PREMEDICATION ON THE INCIDENCE OF INFUSION-RELATED REACTIONS TO ISATUXIMAB AND DESCRIPTION OF RISK FACTORS | 4CPS-141 |
| COMMUNITY PHARMACY-BASED HBA1C SCREENING FOR EARLY DETECTION OF DIABETES AND PRE-DIABETES | 4CPS-142 | |
| A DESCRIPTION OF PHARMACISTS’ INTERVENTIONS TO OPTIMISE THE TREATMENT OF ADULTS WITH ORALLY AVAILABLE COVID-DRUG PAXLOVID® | 4CPS-143 |
| BIOLOGICAL TREATMENTS IN THE PREVENTION OF MIGRAINE: RESTART AND DURATION OF THERAPEUTIC REST | 4CPS-144 | |
| COLLABORATIVE IMPLEMENTATION OF ‘WALANT’ (LOCAL ANESTHETIC) TECHNIQUE IN A HAND SURGERY WARD | 4CPS-145 |
| ECONOMIC IMPACT ON MULTIPLE MYELOMA CLINICAL TRIALS IN THE PHARMACY SERVICE | 4CPS-146 |
| OSIMERTINIB: A PROMISING TREATMENT FOR EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER | 4CPS-147 |
| EAVLUATION OF DAILY DOSE MANUAL DRUG DISPENSING ACCURACY | 4CPS-148 |
| CENTRAL VENOUS CATHETER-RELATED BLOODSTREAM INFECTIONS IN PATIENTS ON TOTAL PARENTERAL NUTRITION | 4CPS-149 | |
| PHARMACEUTICAL INTERVENTIONS IN OBESE PATIENTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION | 4CPS-150 |
| ANALYSIS OF ANTIBIOTIC TREATMENT IN PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA | 4CPS-151 |
| THE INCLUSION OF TRAMADOL FOR PARENTERAL USE IN THE NARCOTIC TABLE OF PHARMACOPOEIA: ANALYSIS OF EFFECTS AND CONSUMPTION IN A GENERAL HOSPITAL SETTING | 4CPS-152 |
| ECONOMIC BENEFIT ANALYSIS ON LUNG CANCER CLINICAL TRIALS: MEDICATION AND MEDICAL TESTS | 4CPS-153 |
| THERAPEUTIC DRUG MONITORING OF AMIKACIN IN NEONATES: ABOUT A NEW PROTOCOL | 4CPS-154 |
| PERCEPTION OF HOSPITAL PHARMACIES ABOUT TELEPHARMACY IN THE PROVISION OF HEALTHCARE FOR PEOPLE LIVING WITH HIV | 4CPS-155 |
| ANALYSIS OF THE PRESCRIPTION PATTERN AND DAYS OF HOSPITALIZATION AVOIDED BY OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY AND THE SAFETY OF THIS PRACTICE | 4CPS-156 |
| PERSPECTIVES OF PATIENTS AND MEDICAL PROVIDERS ON MULTIDISCIPLINARY MEDICATION RECONCILIATIONS SERVICE IN ADULT PATIENTS UNDERGOING THORACIC AND CARDIOVASCULAR SURGERY (MERITS STUDY) | 4CPS-157 |
| RELAPSED/REFRACTORY MULTIPLE MYELOMA AND NEW THERAPEUTIC OPTIONS: EXPERIENCE IN A PHASE I CLINICAL TRIALS UNIT | 4CPS-158 |
| ANALYSIS OF THE INTERVENTIONS CARRIED OUT IN THE GERIATRIC SERVICE IN COLLABORATION WITH THE INTERNAL MEDICINE AND MICROBIOLOGY SERVICES | 4CPS-159 | |
| LONG-TERM EFFECTIVENESS AND SAFETY RESULTS OF GALCANEZUMAB IN REAL-WORLD DATA IN MIGRAINE PROPHYLAXIS | 4CPS-160 |
| VANCOMYCIN PHARMACOKINETIC MONITORING IN CRITICALLY ILL NEONATAL PATIENTS | 4CPS-161 |
| “TO ERR IS HUMAN“: PRESENTING CASES OF MEDICATION ERRORS FROM REAL CLINICAL PRACTICE | 4CPS-162 | |
| EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN HOSPITALISED PATIENTS WITH HYPERKALAEMIA | 4CPS-163 |
| ANALYSIS OF USTEKINUMAB INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE ACCORDING TO LINE OF TREATMENT | 4CPS-164 |
| DETERMINATION OF PREDICTIVE FACTORS FOR IMMUNE-RELATED TOXICITY IN LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY | 4CPS-165 |
| COMPREHENSIVE ASSESSMENT OF PHARMACOTHERAPY IN THE COMPLEX CHRONIC PATIENT: COLLABORATION BETWEEN DIFFERENT LEVELS OF CARE | 4CPS-166 |
| USE OF STANDARD- AND HIGH-DOSE LIPOSOMAL AMPHOTERICIN B AND ITS RELATIONSHIP WITH HYPOMAGNESEMIA | 4CPS-167 | |
| EFFECTIVENESS, SAFETY AND ADHERENCE TO EVOLOCUMAB IN REAL CLINICAL PRACTICE | 4CPS-168 |
| EVALUATION OF ANTICHOLINERGIC DRUG PRESCRIPTION USING A CLINICAL DECISION SUPPORT SYSTEM: A PROSPECTIVE STUDY IN A GERIATRIC REHABILITATION CENTER | 4CPS-169 |
| CLINICAL PHARMACY PRIORITISATION ALGORITHM FOR PATIENTS IN PSYCHIATRIC LONG-TERM CARE: A PILOT STUDY | 4CPS-170 |
| FIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB | 4CPS-171 |
| IMPROVING POST-OPERATIVE ANALGESIA AND ASSOCIATED PRESCRIBING IN THE ORTHOPAEDIC SETTING | 4CPS-172 |
| PRESCRIPTION OF PSYCHOTROPIC DRUGS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON INTEGRASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY | 4CPS-173 |
| NASAL ESKETAMINE USE FOR MAYOR DEPRESSIVE DISORDER, FROM A THIRD LEVEL HOSPITAL TO PERIPHERAL MENTAL CENTERS | 4CPS-174 |
| EFFECTIVENESS OF IMMUNOTHERAPY AS A FUNCTION OF AGE: METHA-ANALYSIS OF THE APPROVED COMBINATIONS IN FIRST LINE METASTASIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITHOUT MUTATIONS. | 4CPS-175 |
| USE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE | 4CPS-176 |
| LONG-ACTING INTRAMUSCULAR ANTIRETROVIRALS: WHAT REAL-WORLD DATA DO WE HAVE? | 4CPS-177 |
| EFFECT OF PCSK9 INHIBITORS ON HYPERCHOLESTEROLEMIA | 4CPS-178 |
| REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH. | 4CPS-179 | |
| SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER TWO YEARS OF EXPERIENCE | 4CPS-180 |
| ELECTRONIC PRESCRIBING IN THE NEONATAL INTENSIVE CARE UNIT: ANALYSIS OF PRESCRIBING ERRORS AND RISK FACTORS | 4CPS-181 |
| DESCRIPTION OF A CLINICAL PHARMACIST INTERVENTION FOCUSED ON MANAGEMENT OF A CHRONIC DISEASE AT HOSPITAL: THE EXAMPLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | 4CPS-182 |
| PHARMACIST-LED OPT-OUT CESSATION TREATMENT PROTOCOL FOR COMBUSTIBLE TOBACCO SMOKING | 4CPS-183 | |
| THERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW | 4CPS-184 |
| ANALYSIS OF THE USE OF MEDICATION NOT INCLUDED IN THE PHARMACOTHERAPEUTIC GUIDE OF A TERTIARY HOSPITAL | 4CPS-185 |
| IMPLEMENTATION OF A PATIENT STRATIFICATION MODEL IN OUTPATIENT PHARMACY FOR IMMUNE-MEDIATED DERMATOLOGICAL DISEASES | 4CPS-186 |
| DEVELOPMENT OF A POPULATION PHARMACOKINETIC MODEL OF CYCLOSPORINE | 4CPS-187 |
| IMPLEMENTATION OF THIOPURINE PHARMACOGENETICS TO IMPROVE PEDIATRIC SAFETY AT A TERTIARY HOSPITAL | 4CPS-188 | |
| LOCAL EXPERIENCE ON THE USE OF CANNABIDIOL FOR THE TREATMENT OF REFRACTORY EPILEPSY. SAFETY AND EFFICACY ON A 10 PATIENT’S COHORT | 4CPS-189 |
| DEVELOPMENT OF TRANSMURAL PHARMACEUTICAL CARE IN A GENERAL HOSPITAL | 4CPS-190 |
| PRE-RADIOIODINE THERAPY SURGICAL MODALITIES: COMPARION OF POST-OPERATIVE THYROGLOBULIN LEVELS IN PATIENTS UNDERGOING 1- OR 2-STEP THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER | 4CPS-191 |
| ASTHMA AND RISK OF CARDIOVASCULAR EVENTS: A RETROSPECTIVE STUDY | 4CPS-192 |
| EFFECTIVENESS AND SAFETY OF INTRAVENOUS USTEKINUMAB INTENSIFICATION IN CROHN’S DISEASE WITH LOSS OF RESPONSE OR PARTIAL RESPONSE TO SUBCUTANEOUS THERAPY | 4CPS-193 |
| EVOLUTION OF HOSPITAL CLINICAL PHARMACY SERVICES IN FINLAND DURING YEARS 2017-2022: A FOLLOW-UP SURVEY | 4CPS-194 |
| CHARACTERIZATION OF INJECTABLE FORMULATIONS AND OPTIMIZATION OF THEIR DELIVERY BY ENTERAL TUBE: A PHYSICOCHEMICAL AND PHYSIOLOGICAL APPROACH | 4CPS-195 |
| ASSESSMENT OF ORAL DRUG THERAPY REGARDING ABSORPTION DISORDERS IN PATIENTS WITH INTESTINAL OSTOMIES – AN OBSERVATIONAL STUDY | 4CPS-196 |
| THE KTIA-SCORAC STUDY : SECURING THE MEDICATION MANAGEMENT OF ELDERLY PATIENTS BY THE SYSTEMATIC EVALUATION OF ANTICHOLINERGIC LOAD SCORES VIA A CLINICAL DECISION SUPPORT SYSTEM | 4CPS-197 |
| EVALUATION OF PROA TEAM INTERVENTION ACCEPTANCE RATES THROUGH AN AUTOMATED MEASUREMENT SYSTEM | 4CPS-198 | |
| COMPARATIVE EVALUATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS | 4CPS-199 |
| TRIPLE THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS BASED ON A PHARMACOLOGICAL TREATMENT ALGORITHM | 4CPS-200 |
| CLINICAL EXPERIENCE OF TYROSINE-KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA | 4CPS-201 |
| EVALUATION OF THE EXCHANGE OF ANTICGRP MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CHRONIC REFRACTORY MIGRAINE | 4CPS-202 |
| DEVELOPMENT AND VALIDATION OF A DATA COLLECTION TOOL TO EVALUATE PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT | 4CPS-203 |
| MONITORING OF LINEZOLID IN HEMODIALYSIS: A CLINICAL CASE | 4CPS-204 |
| RESULTS OF ANTIBIOTIC PROPHYLAXIS IN ACUTE BRONCHOASPIRATION PNEUMONITIS | 4CPS-205 |
| PRE-EXPOSURE PROPHYLAXIS, ARE WE DOING IT RIGHT? | 4CPS-206 |
| EVALUATION OF PROSTATIC SPECIFIC ANTIGEN DEPLETION WITH ABIRATERONE AS A PRONOSTATIVE FACTOR FOR SURVIVAL IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | 4CPS-207 | |
| ANALYSIS OF THE IMPLEMENTATION OF A MULTIDISCIPLINARY PHARMACEUTICAL CARE PROJECT FOR GERIATRIC HEMATO-ONCOLOGY PATIENTS | 4CPS-208 |
| COMPARISON OF TWO PHARMACOKINETIC/PHARMACODYNAMIC INDICES IN CRITICALLY ILL PATIENTS TREATED WITH AMIKACIN | 4CPS-209 |
| HOME INFUSION CHEMOTHERAPY TREATMENT FOR PATIENTS WITH MALIGNANT HAEMATOLOGICAL DISORDERS | 4CPS-210 |
| TITLE: ANALYSIS OF THE PRESCRIPTION OF VITAMIN D SUPPLEMENTS IN A SOCIAL HEALTH CENTER. | 4CPS-211 |
| MANAGEMENT OF POST CAR-T NEUROTOXICITY USING ANAKINRA. A CASE REPORT | 4CPS-212 |
| RESULTS OF ANTIBIOTIC TREATMENT OF AORTIC ENDOPROSTHESIS INFECTIONS IN PATIENTS NOT CANDIDATES FOR SURGERY | 4CPS-213 |
| MONITORING OF TACROLIMUS IN A KIDNEY TRANSPLANTED COHORT | 4CPS-214 |
| ADJUSTMENT OF ANTIBIOTICS THROUGH THE HEMOFILTER: A CASE REPORT | 4CPS-215 |
| EFFICACY AND SAFETY ANALYSIS OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS: REAL-LIFE DATA. | 4CPS-216 |
| A COMPARATIVE EVALUATION OF THE LONG-TERM EFFECTIVENESS OF GUSELKUMAB AND RISANKIZUMAB IN THE CLINICAL MANAGEMENT OF PLAQUE PSORIASIS. | 4CPS-217 |
| OPIOID PRESCRIBING FOR ACUTE NON-CANCER PAIN, POST-OPERATIVE PAIN AND POST-PROCEDURE PAIN BY SURGICAL TEAMS AT A TERTIARY HOSPITAL: 1-DAY AUDIT | 4CPS-218 |
| BEYOND THE EXPECTED: THE ENHANCED DETECTION OF DRUG RELATED PROBLEMS, THE MOST OF A PHARMACEUTICAL DECISION SUPPORT SYSTEM | 4CPS-219 |
| EVALUATION OF THE IMPLEMENTATION OF A PRE-EXPOSURE PROPHYLAXIS PROGRAM. 2 YEARS EXPERIENCE IN OUR REGION | 4CPS-220 |
| EVALUATION OF THE RELEVANCE OF STATINS PRESCRIPTION IN THE ELDERLY : TOWARDS A DEPRESCRIPTION ? | 4CPS-221 |
| THE REAL LIFE OF BENZODIAZEPINES IN GERIATRIC DEPARTMENT : CAN THE PHARMACIST HAVE AN IMPACT ? | 4CPS-222 | |
| A STUDY ON THE PERCEPTION OF ELDERLY PATIENTS ON THE EXPIRATION DATE AND STORAGE OF PRESCRIBED MEDICATION: A QUESTIONNAIRE STUDY | 4CPS-223 |
| MEDICATION RECONCILIATION IN A SURGERY DEPARTMENT: 6-MONTHS EXPERIENCE | 4CPS-224 |
| DEFINING INTERNATIONAL CRITICAL CARE PHARMACIST ASPIRATIONS TO THE MANAGEMENT OF SEPSIS | 4CPS-225 |
| PHARMACEUTICAL INTERVENTION ON THE ADEQUACY OF THE INDICATION OF SEMAGLUTIDE IN DIABETES MELLITUS 2 | 4CPS-226 |
| PHARMACEUTICAL REVIEW AND PHARMACEUTICAL INTERVENTION IN A NURSING HOME TO ENHANCE THE MEDICATION MANAGEMENT OF RESIDENTS. | 4CPS-227 |
| IMPACT AND ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS FOR EARLY MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT | 4CPS-228 |
| SUSTAINABILITY: A PERSON-CENTRED, WHOLE SYSTEMS APPROACH TO MEDICINES OPTIMISATION | 4CPS-229 |
| CLINICAL PHARMACOGENOMICS FOR A SAFER USE OF FLUOROPYRIMIDINES | 4CPS-230 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS | 5PSQ-001 | |
| PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS | 5PSQ-002 | |
| IMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS | 5PSQ-003 |
| COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT | 5PSQ-004 | |
| UTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE | 5PSQ-005 |
| FREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING. | 5PSQ-006 |
| A REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS. | 5PSQ-007 |
| IMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT. | 5PSQ-008 |
| OFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT | 5PSQ-009 |
| NATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS | 5PSQ-010 |
| TOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE | 5PSQ-011 |
| TOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP). | 5PSQ-012 |
| NEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES | 5PSQ-013 |
| ELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL. | 5PSQ-014 |
| ANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG? | 5PSQ-015 |
| ASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT | 5PSQ-016 |
| PHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS | 5PSQ-017 |
| ANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK. | 5PSQ-018 |
| VALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION | 5PSQ-019 |
| EVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT. | 5PSQ-020 |
| EVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT. | 5PSQ-021 |
| DRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) | 5PSQ-022 |
| SAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY | 5PSQ-023 |
| ENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL | 5PSQ-024 |
| AUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION | 5PSQ-025 |
| THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS | 5PSQ-026 | |
| VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS | 5PSQ-027 | |
| CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA | 5PSQ-028 | |
| THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS | 5PSQ-029 | |
| CONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT | 5PSQ-030 |
| “ASSESSING HEALTHCARE PROFESSIONALS “VIEWS ON DEPRESCRIPTION | 5PSQ-031 | |
| USE OF THE “PRECAUTIONARY ANNULMENTS” TOOL BY A HOSPITAL PHARMACY SERVICE | 5PSQ-032 | |
| TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE | 5PSQ-033 | |
| COMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER | 5PSQ-034 |
| SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY | 5PSQ-035 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT | 5PSQ-036 |
| PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER | 5PSQ-037 |
| REAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 5PSQ-038 |
| IMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS | 5PSQ-039 |
| VOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT | 5PSQ-040 |
| IMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY | 5PSQ-041 |
| FOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL’S ELECTRONIC INCIDENT REPORTING SYSTEM | 5PSQ-042 |
| DESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME | 5PSQ-043 |
| SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE | 5PSQ-044 |
| ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS | 5PSQ-045 |
| SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT | 5PSQ-046 | |
| THE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY | 5PSQ-047 |
| COST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY | 5PSQ-048 |
| MEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT | 5PSQ-049 |
| IT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL? | 5PSQ-050 |
| EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19. | 5PSQ-051 |
| ANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA | 5PSQ-052 |
| EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS. | 5PSQ-053 | |
| EVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE | 5PSQ-054 |
| EFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT | 5PSQ-055 |
| VACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC | 5PSQ-056 |
| ANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS | 5PSQ-057 |
| EFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA. | 5PSQ-058 |
| STUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL | 5PSQ-059 |
| REAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL | 5PSQ-060 |
| CURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL | 5PSQ-061 |
| SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY | 5PSQ-062 | |
| ADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT | 5PSQ-063 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL. | 5PSQ-064 |
| INTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT. | 5PSQ-065 |
| SURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE | 5PSQ-066 |
| DRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY | 5PSQ-067 |
| THE HOSPITAL PHARMACIST’S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS | 5PSQ-068 |
| COMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING | 5PSQ-069 |
| DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE. | 5PSQ-070 |
| MULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT | 5PSQ-071 |
| TREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY. | 5PSQ-072 |
| RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS | 5PSQ-073 |
| PHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT | 5PSQ-074 |
| ADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION | 5PSQ-075 |
| EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE | 5PSQ-076 |
| ADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19) | 5PSQ-077 |
| HYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE | 5PSQ-078 |
| PHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA | 5PSQ-079 |
| CLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION | 5PSQ-080 |
| SATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE | 5PSQ-081 |
| THIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES? | 5PSQ-082 |
| MARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT. | 5PSQ-083 |
| EROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT. | 5PSQ-084 |
| SAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE | 5PSQ-085 |
| ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES | 5PSQ-086 | |
| ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS | 5PSQ-087 |
| ADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS | 5PSQ-088 |
| OUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-19 | 5PSQ-089 |
| CAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | 5PSQ-090 |
| SUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT | 5PSQ-091 |
| ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION | 5PSQ-092 | |
| DOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS? | 5PSQ-093 |
| INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE. | 5PSQ-094 | |
| HOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA | 5PSQ-095 |
| DESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART | 5PSQ-096 |
| AN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY | 5PSQ-097 |
| PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES | 5PSQ-098 | |
| DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME | 5PSQ-099 | |
| SURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS | 5PSQ-100 |
| MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE | 5PSQ-101 | |
| ANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION | 5PSQ-102 |
| VANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE | 5PSQ-103 |
| REAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS? | 5PSQ-104 |
| PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS | 5PSQ-105 | |
| FALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES | 5PSQ-106 |
| COMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ? | 5PSQ-107 |
| EFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT | 5PSQ-108 |
| HAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS | 5PSQ-109 |
| DESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS | 5PSQ-110 |
| SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION | 5PSQ-111 |
| A SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE | 5PSQ-112 |
| ROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM | 5PSQ-113 |
| HEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS | 5PSQ-114 |
| EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE) | 5PSQ-115 | |
| REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS | 5PSQ-116 |
| TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND? | 5PSQ-117 |
| NON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME | 5PSQ-118 |
| REVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON | 5PSQ-119 |
| PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY | 5PSQ-120 |
| A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE | 5PSQ-121 |
| SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING | 5PSQ-122 | |
| SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF | 5PSQ-123 | |
| THE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY | 5PSQ-124 |
| ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT | 5PSQ-125 | |
| THE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS | 5PSQ-126 |
| MEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS | 5PSQ-127 |
| COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS | 5PSQ-128 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS | 5PSQ-001 | |
| PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS | 5PSQ-002 | |
| IMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS | 5PSQ-003 |
| COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT | 5PSQ-004 | |
| UTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE | 5PSQ-005 |
| FREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING. | 5PSQ-006 |
| A REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS. | 5PSQ-007 |
| IMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT. | 5PSQ-008 |
| OFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT | 5PSQ-009 |
| NATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS | 5PSQ-010 |
| TOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE | 5PSQ-011 |
| TOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP). | 5PSQ-012 |
| NEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES | 5PSQ-013 |
| ELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL. | 5PSQ-014 |
| ANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG? | 5PSQ-015 |
| ASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT | 5PSQ-016 |
| PHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS | 5PSQ-017 |
| ANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK. | 5PSQ-018 |
| VALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION | 5PSQ-019 |
| EVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT. | 5PSQ-020 |
| EVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT. | 5PSQ-021 |
| DRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) | 5PSQ-022 |
| SAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY | 5PSQ-023 |
| ENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL | 5PSQ-024 |
| AUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION | 5PSQ-025 |
| THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS | 5PSQ-026 | |
| VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS | 5PSQ-027 | |
| CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA | 5PSQ-028 | |
| THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS | 5PSQ-029 | |
| CONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT | 5PSQ-030 |
| “ASSESSING HEALTHCARE PROFESSIONALS “VIEWS ON DEPRESCRIPTION | 5PSQ-031 | |
| USE OF THE “PRECAUTIONARY ANNULMENTS” TOOL BY A HOSPITAL PHARMACY SERVICE | 5PSQ-032 | |
| TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE | 5PSQ-033 | |
| COMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER | 5PSQ-034 |
| SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY | 5PSQ-035 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT | 5PSQ-036 |
| PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER | 5PSQ-037 |
| REAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 5PSQ-038 |
| IMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS | 5PSQ-039 |
| VOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT | 5PSQ-040 |
| IMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY | 5PSQ-041 |
| FOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL’S ELECTRONIC INCIDENT REPORTING SYSTEM | 5PSQ-042 |
| DESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME | 5PSQ-043 |
| SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE | 5PSQ-044 |
| ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS | 5PSQ-045 |
| SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT | 5PSQ-046 | |
| THE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY | 5PSQ-047 |
| COST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY | 5PSQ-048 |
| MEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT | 5PSQ-049 |
| IT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL? | 5PSQ-050 |
| EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19. | 5PSQ-051 |
| ANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA | 5PSQ-052 |
| EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS. | 5PSQ-053 | |
| EVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE | 5PSQ-054 |
| EFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT | 5PSQ-055 |
| VACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC | 5PSQ-056 |
| ANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS | 5PSQ-057 |
| EFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA. | 5PSQ-058 |
| STUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL | 5PSQ-059 |
| REAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL | 5PSQ-060 |
| CURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL | 5PSQ-061 |
| SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY | 5PSQ-062 | |
| ADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT | 5PSQ-063 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL. | 5PSQ-064 |
| INTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT. | 5PSQ-065 |
| SURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE | 5PSQ-066 |
| DRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY | 5PSQ-067 |
| THE HOSPITAL PHARMACIST’S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS | 5PSQ-068 |
| COMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING | 5PSQ-069 |
| DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE. | 5PSQ-070 |
| MULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT | 5PSQ-071 |
| TREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY. | 5PSQ-072 |
| RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS | 5PSQ-073 |
| PHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT | 5PSQ-074 |
| ADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION | 5PSQ-075 |
| EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE | 5PSQ-076 |
| ADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19) | 5PSQ-077 |
| HYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE | 5PSQ-078 |
| PHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA | 5PSQ-079 |
| CLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION | 5PSQ-080 |
| SATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE | 5PSQ-081 |
| THIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES? | 5PSQ-082 |
| MARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT. | 5PSQ-083 |
| EROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT. | 5PSQ-084 |
| SAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE | 5PSQ-085 |
| ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES | 5PSQ-086 | |
| ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS | 5PSQ-087 |
| ADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS | 5PSQ-088 |
| OUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-19 | 5PSQ-089 |
| CAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | 5PSQ-090 |
| SUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT | 5PSQ-091 |
| ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION | 5PSQ-092 | |
| DOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS? | 5PSQ-093 |
| INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE. | 5PSQ-094 | |
| HOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA | 5PSQ-095 |
| DESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART | 5PSQ-096 |
| AN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY | 5PSQ-097 |
| PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES | 5PSQ-098 | |
| DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME | 5PSQ-099 | |
| SURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS | 5PSQ-100 |
| MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE | 5PSQ-101 | |
| ANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION | 5PSQ-102 |
| VANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE | 5PSQ-103 |
| REAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS? | 5PSQ-104 |
| PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS | 5PSQ-105 | |
| FALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES | 5PSQ-106 |
| COMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ? | 5PSQ-107 |
| EFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT | 5PSQ-108 |
| HAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS | 5PSQ-109 |
| DESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS | 5PSQ-110 |
| SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION | 5PSQ-111 |
| A SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE | 5PSQ-112 |
| ROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM | 5PSQ-113 |
| HEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS | 5PSQ-114 |
| EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE) | 5PSQ-115 | |
| REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS | 5PSQ-116 |
| TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND? | 5PSQ-117 |
| NON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME | 5PSQ-118 |
| REVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON | 5PSQ-119 |
| PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY | 5PSQ-120 |
| A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE | 5PSQ-121 |
| SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING | 5PSQ-122 | |
| SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF | 5PSQ-123 | |
| THE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY | 5PSQ-124 |
| ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT | 5PSQ-125 | |
| THE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS | 5PSQ-126 |
| MEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS | 5PSQ-127 |
| COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS | 5PSQ-128 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| DEVELOPING THE ROLE OF PRIMARY CARE CLINICAL PHARMACIST | NP-001 |
| “CAPSULE PHARMA”, AN INNOVATIVE DIGITAL TRAINING TOOL TO LEARN ABOUT IMPORTANT STERILE MEDICAL DEVICE (SMD) CONCEPTS | NP-002 |
| PHARMACEUTICAL INFUSION SCHEDULES AS A TOOL TO IMPROVE FLUID RESTRICTION IN PICU PATIENTS | NP-003 | |
| RETROSPECTIVE STUDY ON INDIVIDUALISED MEDICATION OF DEMENTIA PATIENTS RECEIVING CHRONIC HOSPITAL CARES | NP-004 |
| SELF-ASSESSMENT ON THE IMPLEMENTATION OF RECOMMENDATIONS OF THE PERIOPERATIVE PROCESS: INFECTIOUS RISK MANAGEMENT IN SURGERY SETTING | NP-005 |
| IMMUNOTHERAPY IN SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER | NP-006 |
| RECOMMENDATIONS FOR ADMINISTRATION OF IMMUNOSUPPRESSANTS VIA ENTERAL FEEDING TUBE ACCORDING TO THEIR IN-VITRO ADMINISTRATION | NP-007 |
| EMERGENCY DEPARTMENT REVISIT SOCORE BASED ON PHARMACOTHERPAY | NP-008 |
| ASSESSMENT OF MEDICATION DISCREPANCIES BY PHARMACIST-LED MEDICATION RECONCILIATION AT ADMISSION : A PROSPECTIVE STUDY IN TRAUMATOLOGY | NP-009 |
| DEVELOPMENT OF A 2% LIDOCAINE GEL FOR LOCAL ANAESTHESIA OF THE EYE PRIOR TO INTRAVITREAL INJECTION | NP-010 |
| Around one-third of people with diabetes will develop foot ulcers in their lifetime | Student Science Award |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION | 1ISG-001 |
| MEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT’S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF | 1ISG-002 |
| PROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS | 1ISG-003 |
| HOME DELIVERY – EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES – COMPARISON OF ASSISTANCE MODELS | 1ISG-004 | |
| DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY | 1ISG-005 | |
| OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) – REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS | 1ISG-006 | |
| OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD) | 1ISG-007 | |
| THE MULTIDISCIPLINARY ASSESSMENT OF RAPID ANTIGEN TESTS FOR THE DETECTION OF THE OMICRON VARIANT: THE ROLE OF THE HOSPITAL PHARMACIST IN A UNIVERSITY HOSPITAL | 1ISG-008 |
| A FRAMEWORK FACILITATING ACCESS TO MEDICINES IN THE EUROPEAN UNION | 1ISG-009 |
| PHARMACY STAFF SATISFACTION AND OPINION OF NEW WEBSITE APPLICATION FOR OUTPATIENT CARE | 1ISG-010 |
| MANAGEMENT OF UNADMINISTERED THERAPIES: IMPACT OF PHARMACIST-DOCTOR COLLABORATION TO OPTIMIZE THE PROCESS OF PREPARING CANCER THERAPIES | 1ISG-011 |
| COST-MINIMISATION ANALYSIS: PROPHYLACTIC TREATMENT OF HAEMOPHILIA TYPE A, WHAT TO CHOOSE BETWEEN FACTOR VIII, RECOMBINANT FACTORS VIII (MOROCTOCOG-ALFA AND OCTOCOG) AND EMICIZUMAB? | 1ISG-012 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| USE AND COST EVOLUTION OF INFLIXIMAB AND ADALIMUMAB OVER 8 YEARS IN A TERTIARY HOSPITAL | 2SPD-001 |
| COST SAVINGS IMPACT OF GENERICS: A LOCAL EXPERIENCE ON LENALIDOMIDE | 2SPD-002 | |
| ERRORS DETECTED IN THE TELEPHARMACY PROCEDURE | 2SPD-003 |
| ECONOMIC EVALUATION AND BUDGET IMPACT FOR A REGIONAL HEALTH SERVICE ASSOCIATED WITH THE INCLUSION OF THE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN A REGIONAL PHARMACOTHERAPEUTIC GUIDELINE | 2SPD-004 |
| NEW CLOSED SYSTEM TRANSFER DEVICE CONTAINS REAL DRUG VAPOURS FOR UP TO 28 DAYS | 2SPD-005 |
| ARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES? | 2SPD-006 |
| USE OF DRUGS IN SPECIAL SITUATIONS | 2SPD-007 |
| BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE | 2SPD-008 | |
| AVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS | 2SPD-009 |
| REVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION | 2SPD-010 |
| COMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE | 2SPD-011 |
| COMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS | 2SPD-012 |
| INTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES | 2SPD-013 |
| COST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY | 2SPD-014 |
| INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS | 2SPD-015 | |
| COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | 2SPD-016 | |
| TELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY | 2SPD-017 |
| BEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT | 2SPD-018 |
| EXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE | 2SPD-019 |
| IMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY’S WORKLOAD: LESSONS LEARNED | 2SPD-020 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| PREPACKED BOXES FOR OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) – A QUESTIONNAIRE SURVEY ON KNOWLEDGE, OPINION AND WISHES | 3PC-001 |
| HAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION – IS THERE A NEED TO REDUCE EXPOSURE? | 3PC-002 |
| 99m-Tc- HMPAO LABELED LEUKOCITES: STUDYING ACUTE INFECTION OUTBREAKS – NUCLEAR PHARMACIST IN NUCLEAR MEDICINE | 3PC-003 | |
| ECONOMIC SAVINGS OF ERENUMAB REDOSING IN A THIRD LEVEL HOSPITAL | 3PC-004 |
| CLOSED SYSTEM TRANSFER DEVICE (CSTD) EXTENDS PRACTICAL IN-USE SHELF LIFE TO 28 DAYS AFTER FIRST PUNCTURE OF NON-PRESERVED SINGLE-USE-VIALS IN BOTH CONTROLLED AND UNCONTROLLED ENVIRONMENTS | 3PC-005 |
| CONTAINER CLOSURE INTEGRITY TESTING AND PROCES VALIDATION OF CLOSED SYSTEM TRANSFER DEVICES FOR ASEPTIC RECONSTITUTION OF DRUG VIALS CONNECTED TO FLUID BAGS | 3PC-006 |
| IMPACT OF A SUSTAINABILITY STRATEGY IN THE DEVELOPMENT OF STANDARDIZED NEONATAL PARENTERAL NUTRITION ON DEMAND | 3PC-007 | |
| SLOW ANAKINRA DESENSITIZATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION | 3PC-008 |
| CYCLOPHOSPHAMIDE SURFACE CONTAMINATION IN A ROBOTIC CHEMOTHERAPY COMPOUNDING PROCESS | 3PC-009 |
| FORMULATION OF TACROLIMUS SOLUTION FOR SUBLINGUAL USE | 3PC-010 |
| A VIRTUAL STERILISATION AREA : AN INTERACTIVE TRAINING TOOL | 3PC-011 |
| IMPACT AND SATISFACTION IN DRUG ADDICTS ATTENTION CENTERS AFTER INCREASING THE STABILITY OF METHADONE ORAL SOLUTION | 3PC-012 |
| FORMULATION AND ELABORATION OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF A MENINGEAL CARCINOMATOSIS | 3PC-013 |
| METAMORPHINE INSTEAD OF POLYSUBSTANCE USE? | 3PC-014 |
| IN-USE STABILITY OF COMIRNATY AND SPIKEVAX CLINICAL SOLUTIONS: PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES. A COMPARATIVE STUDY FROM A HOSPITAL PHARMACY PERSPECTIVE | 3PC-015 |
| DOES A HOSPITAL COMPRESSOR SYSTEM CONTINOUSLY DELIVER MEDICINAL AIR ACCORDING TO THE EUROPEAN PHARMACOPAEIA? | 3PC-016 |
| IMPACT OF AGITATION ON PEMBROLIZUMAB (KEYTRUDA®) SAFETY AND EFFICACY: AGGREGATION AND FUNCTIONALITY. | 3PC-017 |
| TIME TO AVAILABILITY OF INJECTABLE ANTICANCER DRUGS FOR OUTPATIENTS: REASSESSMENT IN A FRENCH COMPREHENSIVE CANCER CENTER | 3PC-018 | |
| INDIGO CARMINE SOLUTION AND ADRENALINE IN SUBMUCOSAL CHROMOENDOSCOPY | 3PC-019 |
| CLOBETASOL PETROLATUM OINTMENT 0.015% FOR THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS: A CASE REPORT. | 3PC-020 |
| AMPHOTERICIN AND COLISTIN GELS FOR NECROTIZING WOUNDS: GALENIC AND MICROBIOLOGICAL VALIDATION. | 3PC-021 |
| FORMULATION AND QUALITY CONTROL OF A BISOPROLOL 0.5 MG/ML ORAL SOLUTION FOR PAEDIATRIC USE | 3PC-022 |
| PATCH TESTS WITH ETHAMBUTOL 10%, ISONIAZID 15% AND PYRAZINAMIDE 25%: A CASE REPORT. | 3PC-023 |
| THE PREPARATION PERSONALIZED OF IMMUNOGLOBULIN BAGS TO IMPROVE THE TREATMENT PATH OF NEUROLOGICAL PATIENTS | 3PC-024 |
| OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT): AN EXAMPLE DURING THE COVID-19 HEALTH EMERGENCY. | 3PC-025 | |
| EFFECTIVENESS AND SAFETY OF INSULIN 1UI/ml EYE DROPS | 3PC-026 |
| STABILITY OF TACROLIMUS ORAL SUSPENSION IN DISPOSABLE POLYPROPYLENE SYRINGE | 3PC-027 |
| FORMULATION OF AN ORAL PLATELET LYSATE GEL TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE ASSOCIATED ORAL MUCOSITIS. EFFECTIVENESS IN A SERIES OF CASES | 3PC-028 |
| MANAGEMENT OF A CHEMOTHERAPY PRODUCTION AFTER A CYBER-ATTACK IN A PUBLIC HOSPITAL | 3PC-029 |
| EVALUATION OF EXCIPIENTS USED IN PAEDIATRIC COMPOUNDED FORMULATIONS PRESCRIBED IN A NEONATAL INTENSIVE CARE UNIT | 3PC-030 |
| A DELPHI METHOD TO STANDARDIZE THE PREPARATION OF AUTOLOGOUS SERUM EYE DROPS ? | 3PC-031 |
| USE OF ORAL KETAMINE FORMULATION IN PATIENTS WITH CHRONIC REFRACTORY PAIN | 3PC-032 | |
| ECONOMIC IMPACT OF CENTRALIZING PEDIATRIC INTRAVENOUS ADMIXTURES | 3PC-033 |
| USE OF A MIXTURE OF BLEOMYCIN, LIDOCAINE AND EPINEPHRINE IN THE TREATMENT OF KELOID SCARS.ON THE SUBJECT OF A CASE. | 3PC-034 | |
| GALENIC DEVELOPMENT OF A GENERIC SPECIALTY WITH CONVENTIONAL RELEASE BASED ON ACARBOSE | 3PC-035 |
| CENTRALIZED AND PERSONALIZED PREPARATION OF INTRAVENOUS KETAMINE FOR PATIENTS WITH RESISTANT DEPRESSION | 3PC-036 |
| LIQUID CHROMATOGRAPY MASS SPECTROMETRY ANALYSIS OF DOXORUBICIN AND EPIRUBICIN AFTER FREEZING | 3PC-037 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT. | 4CPS-001 |
| SAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE | 4CPS-002 |
| EXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW | 4CPS-003 |
| TRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL | 4CPS-004 |
| SUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT | 4CPS-005 |
| COMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN | 4CPS-006 |
| TARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE. | 4CPS-007 |
| DOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS? | 4CPS-008 |
| Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY | 4CPS-009 |
| DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY | 4CPS-010 |
| CLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL | 4CPS-011 |
| PLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY | 4CPS-012 |
| TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY. | 4CPS-013 | |
| COMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS | 4CPS-014 |
| ROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT | 4CPS-015 |
| PREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS | 4CPS-016 |
| REAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. | 4CPS-017 |
| EVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS | 4CPS-018 |
| QUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS | 4CPS-019 |
| TREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS. | 4CPS-020 |
| EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY | 4CPS-021 | |
| ADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION | 4CPS-022 |
| TOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY | 4CPS-023 |
| COMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION | 4CPS-024 |
| FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’ | 4CPS-025 | |
| EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS | 4CPS-026 |
| COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA. | 4CPS-027 |
| DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY | 4CPS-028 | |
| ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES | 4CPS-029 |
| IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES | 4CPS-030 |
| THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES | 4CPS-031 |
| THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS – A RETROSPECTIVE ANALYSIS | 4CPS-032 | |
| EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE | 4CPS-033 |
| ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19 | 4CPS-034 |
| ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE | 4CPS-035 |
| SUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT | 4CPS-036 |
| INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS | 4CPS-037 |
| CHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY | 4CPS-038 |
| CLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS. | 4CPS-039 |
| ELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS | 4CPS-040 |
| ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT | 4CPS-041 |
| OFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT | 4CPS-042 |
| DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS | 4CPS-043 |
| EFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT | 4CPS-044 |
| ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE | 4CPS-045 | |
| A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT | 4CPS-046 | |
| IMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY | 4CPS-047 |
| ANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN | 4CPS-048 |
| TELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS | 4CPS-049 |
| ANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | 4CPS-050 |
| IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS | 4CPS-051 | |
| LONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH) | 4CPS-052 |
| KOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT | 4CPS-053 |
| USE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT. | 4CPS-054 |
| EFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER. | 4CPS-055 |
| A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE | 4CPS-056 | |
| SEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT. | 4CPS-057 |
| SYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA | 4CPS-058 |
| EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS | 4CPS-059 | |
| EFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER | 4CPS-060 |
| APPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS | 4CPS-061 |
| EVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT | 4CPS-062 |
| USING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING | 4CPS-063 |
| EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN. | 4CPS-064 |
| SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT | 4CPS-065 | |
| BIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL | 4CPS-066 |
| A CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY | 4CPS-067 |
| CONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS | 4CPS-068 |
| EXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC | 4CPS-069 |
| THE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS | 4CPS-070 |
| IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS | 4CPS-071 | |
| REAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL | 4CPS-072 |
| ANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM | 4CPS-073 |
| EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL | 4CPS-074 |
| PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS | 4CPS-075 |
| EFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA. | 4CPS-076 |
| CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE | 4CPS-077 |
| ASSESSMENT OF THE QUALITY OF A HOSPITAL’S CLINICAL TRIAL INITIATION VISIT | 4CPS-078 |
| COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION | 4CPS-079 |
| OPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE. | 4CPS-080 |
| EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV | 4CPS-081 | |
| MOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN | 4CPS-082 |
| CREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING | 4CPS-083 |
| EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION | 4CPS-084 |
| PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT | 4CPS-085 | |
| COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. | 4CPS-086 | |
| PERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS | 4CPS-087 |
| CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB | 4CPS-088 |
| CURRENT STATUS OF HEPATITIS C VIRUS INFECTION | 4CPS-089 |
| A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES | 4CPS-090 | |
| WHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST | 4CPS-091 |
| STATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS | 4CPS-092 |
| POLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA | 4CPS-093 |
| ANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT | 4CPS-094 |
| INFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES | 4CPS-095 |
| EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS | 4CPS-096 | |
| COMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS. | 4CPS-097 |
| NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS | 4CPS-098 |
| NINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL | 4CPS-099 |
| VALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST | 4CPS-100 |
| CAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE | 4CPS-101 |
| DRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT | 4CPS-102 |
| PHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT | 4CPS-103 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA | 4CPS-104 |
| CEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA | 4CPS-105 |
| BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD | 4CPS-106 |
| EFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN | 4CPS-107 |
| PATIENT AND PHYSICIANS’S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL | 4CPS-108 |
| THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA | 4CPS-109 |
| ASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS | 4CPS-110 |
| IMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE | 4CPS-111 |
| SURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC | 4CPS-112 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL | 4CPS-113 |
| DEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT | 4CPS-114 |
| DEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING | 4CPS-115 |
| THE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW | 4CPS-116 |
| USE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS | 4CPS-117 |
| HEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL | 4CPS-118 |
| PNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA | 4CPS-119 |
| ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT» | 4CPS-120 |
| ANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS | 4CPS-121 |
| CLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE | 4CPS-122 |
| CASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS | 4CPS-123 |
| EFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL | 4CPS-124 |
| PREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION | 4CPS-125 |
| LINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL | 4CPS-126 |
| PHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION | 4CPS-127 |
| CLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA. | 4CPS-128 |
| REAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER | 4CPS-129 |
| EVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-130 |
| SOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS | 4CPS-131 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION | 4CPS-132 |
| SAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS | 4CPS-133 |
| PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 – 2021 | 4CPS-134 | |
| MELANOMA ADJUVANT THERAPY: from trials to clinical practice215 | 4CPS-135 |
| STANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE | 4CPS-136 |
| EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL | 4CPS-137 |
| USE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES | 4CPS-138 |
| THE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ? | 4CPS-139 |
| MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY | 4CPS-140 | |
| PHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE | 4CPS-141 |
| EVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE | 4CPS-142 |
| CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART. | 4CPS-143 |
| EXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION | 4CPS-144 |
| CONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST | 4CPS-145 |
| ‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION | 4CPS-146 |
| REAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC) | 4CPS-147 |
| USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION | 4CPS-148 | |
| PAIN MANAGEMENT IN MENTAL HEALTH. | 4CPS-149 |
| THE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT | 4CPS-150 |
| ACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER | 4CPS-151 |
| PERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT. | 4CPS-152 |
| OFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST | 4CPS-153 |
| IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW | 4CPS-154 |
| CREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS | 4CPS-155 |
| ANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL | 4CPS-156 |
| COMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL | 4CPS-157 |
| IMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT | 4CPS-158 |
| ESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION | 4CPS-159 |
| REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS | 4CPS-160 |
| NEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE | 4CPS-161 |
| TRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION. | 4CPS-162 |
| CYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY | 4CPS-163 |
| ADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE. | 4CPS-164 |
| ADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL. | 4CPS-165 |
| IMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME | 4CPS-166 |
| CURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER | 4CPS-167 |
| RESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE | 4CPS-168 |
| PHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES | 4CPS-169 |
| THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN | 4CPS-170 | |
| METHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE | 4CPS-171 |
| BRODALUMAB’S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE | 4CPS-172 |
| EVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES | 4CPS-173 |
| EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS | 4CPS-174 | |
| SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS | 4CPS-175 |
| EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS | 4CPS-176 |
| OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT | 4CPS-177 |
| DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS | 4CPS-178 |
| REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION | 4CPS-179 | |
| VANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION | 4CPS-180 |
| FOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL | 4CPS-181 |
| EXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE | 4CPS-182 |
| EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING | 4CPS-183 |
| WHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY? | 4CPS-184 |
| COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY | 4CPS-185 | |
| EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-186 |
| PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19 | 4CPS-187 |
| QUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT | 4CPS-188 |
| ANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES | 4CPS-189 |
| ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT? | 4CPS-190 |
| IMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS | 4CPS-191 |
| ANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY | 4CPS-192 |
| SUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME | 4CPS-193 |
| BASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION | 4CPS-194 |
| E-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS | 4CPS-195 |
| POTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV | 4CPS-196 |
| CONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE? | 4CPS-197 |
| ANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL | 4CPS-198 |
| PHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN | 4CPS-199 |
| SUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS | 4CPS-200 |
| PHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON | 4CPS-201 |
| THE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT | 4CPS-202 |
| ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW | 4CPS-203 |
| NATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY | 4CPS-204 |
| PHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT | 4CPS-205 |
| EVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS | 4CPS-206 |
| PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA | 4CPS-207 | |
| TELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES | 4CPS-208 |
| EXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS. | 4CPS-209 |
| EFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL | 4CPS-210 |
| DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS’S KNOWLEDGE | 4CPS-211 | |
| SPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS | 4CPS-212 |
| CHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT | 4CPS-213 |
| REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER | 4CPS-214 |
| DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS. | 4CPS-215 |
| OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH’S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT | 4CPS-216 | |
| THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION | 4CPS-217 |
| TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS | 4CPS-218 | |
| AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT | 4CPS-219 |
| COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS. | 4CPS-220 |
| ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE | 4CPS-221 |
| HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA | 4CPS-222 |
| BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS | 4CPS-223 |
| IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS | 4CPS-224 |
| HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs) | 4CPS-225 |
| CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS? | 4CPS-226 |
| REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN | 4CPS-227 |
| HIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS | 4CPS-228 |
| THE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST | 4CPS-229 |
| ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA | 4CPS-230 |
| EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS | 4CPS-231 | |
| COMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS | 4CPS-232 |
| PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE | 4CPS-233 |
| DEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA | 4CPS-234 |
| IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS | 4CPS-235 | |
| LOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV | 4CPS-236 |
| HYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS. | 4CPS-237 |
| PROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT. | 4CPS-238 |
| POPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS | 4CPS-239 |
| FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | 4CPS-240 | |
| FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL | 4CPS-241 |
| ISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING. | 4CPS-242 |
| DELAYED HIV TREATMENT AND FACTORS ASSOCIATED | 4CPS-243 |
| ANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS | 4CPS-244 |
| PREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS | 4CPS-245 |
| TREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT | 4CPS-246 |
| INITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY | 4CPS-247 |
| THERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS | 4CPS-248 |
| RELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS. | 4CPS-249 |
| EXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT | 4CPS-250 |
| HEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN | 4CPS-251 |
| OPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT | 4CPS-252 |
| DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL | 4CPS-253 | |
| DAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE | 4CPS-254 |
| ANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY | 4CPS-255 |
| ENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES | 4CPS-256 |
| PREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY | 4CPS-257 |
| PHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL | 4CPS-258 |
| MANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT | 4CPS-259 |
| PERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA | 4CPS-260 |
| ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION. | 4CPS-261 | |
| A NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY | 4CPS-262 |
| THE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP) | 4CPS-263 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT | 5PSQ-001 |
| PHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS) | 5PSQ-002 |
| PERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT | 5PSQ-003 |
| EPCLUSA RELATED SLEEPINESS: A CASE REPORT | 5PSQ-004 |
| ANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA | 5PSQ-005 |
| IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: A 7-MONTHS ANALYSIS | 5PSQ-006 |
| IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: WHAT’S NEW AND WHAT’S LEFT? | 5PSQ-007 |
| A DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES. | 5PSQ-008 |
| EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS | 5PSQ-009 |
| DIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE | 5PSQ-010 |
| PHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION | 5PSQ-011 |
| CASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS – 24 MONTHS OF FOLLOW-UP | 5PSQ-012 |
| PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE. | 5PSQ-013 |
| IMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL – TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY) | 5PSQ-014 |
| PERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM | 5PSQ-015 |
| HUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS – A STUDY BASED ON INCIDENT REPORTS | 5PSQ-016 |
| IMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN. | 5PSQ-017 |
| PRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY? | 5PSQ-018 |
| ANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL | 5PSQ-019 |
| ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT | 5PSQ-020 | |
| AUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING | 5PSQ-021 |
| ANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE | 5PSQ-022 |
| SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT | 5PSQ-023 |
| HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING | 5PSQ-024 |
| IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE. | 5PSQ-025 |
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS | 5PSQ-026 |
| APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA | 5PSQ-027 |
| CDK 4/6 INHIBITORS – ANALYSIS OF POTENTIAL DRUG INTERACTIONS | 5PSQ-028 |
| PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME | 5PSQ-029 |
| SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA | 5PSQ-030 |
| ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED | 5PSQ-031 |
| PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM | 5PSQ-032 |
| ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B | 5PSQ-033 |
| FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING | 5PSQ-034 |
| MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA | 5PSQ-035 |
| MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA | 5PSQ-036 |
| IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION | 5PSQ-037 |
| DRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS | 5PSQ-038 |
| RAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE. | 5PSQ-039 |
| ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE | 5PSQ-040 | |
| STERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT | 5PSQ-041 |
| PREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA. | 5PSQ-042 |
| UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST | 5PSQ-043 | |
| REAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS | 5PSQ-044 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS | 5PSQ-045 |
| FMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST | 5PSQ-046 |
| PRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY | 5PSQ-047 |
| WHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS. | 5PSQ-048 |
| ASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL | 5PSQ-049 |
| ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE | 5PSQ-050 |
| PARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT | 5PSQ-051 |
| CHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS | 5PSQ-052 |
| DESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX | 5PSQ-053 |
| ASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI) | 5PSQ-054 |
| SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR) | 5PSQ-055 | |
| HETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE | 5PSQ-056 |
| EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE | 5PSQ-057 |
| MANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE | 5PSQ-058 |
| REAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT | 5PSQ-059 |
| GLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL. | 5PSQ-060 |
| NEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS | 5PSQ-061 |
| REVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS. | 5PSQ-062 |
| A CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS | 5PSQ-063 |
| CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT | 5PSQ-064 |
| BE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE | 5PSQ-065 |
| ADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE | 5PSQ-066 |
| TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES | 5PSQ-067 | |
| DIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS | 5PSQ-068 |
| ANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES. | 5PSQ-069 |
| PHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT | 5PSQ-070 |
| ANALYSIS OF MEDICATION PROVIDED BY PATIENTS | 5PSQ-071 |
| ANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY. | 5PSQ-072 |
| IS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE | 5PSQ-073 |
| INTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL | 5PSQ-074 |
| PROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT | 5PSQ-075 |
| PATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION | 5PSQ-076 |
| CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS – REAL-WORLD DATA ANALYSIS | 5PSQ-077 | |
| ANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-19 | 5PSQ-078 |
| FONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT. | 5PSQ-079 |
| IDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT | 5PSQ-080 |
| ASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC | 5PSQ-081 |
| GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS. | 5PSQ-082 | |
| FOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY | 5PSQ-083 |
| ASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES | 5PSQ-084 |
| MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM | 5PSQ-085 |
| ANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME | 5PSQ-086 |
| EVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES | 5PSQ-087 |
| EXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL | 5PSQ-088 |
| CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS? | 5PSQ-089 | |
| STUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM. | 5PSQ-090 |
| TRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION | 5PSQ-091 |
| PHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT | 5PSQ-092 |
| PHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM | 5PSQ-093 |
| TOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE | 5PSQ-094 |
| CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY | 5PSQ-095 | |
| A PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT. | 5PSQ-096 |
| HEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION | 5PSQ-097 |
| SAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES | 5PSQ-098 |
| ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL | 5PSQ-099 |
| UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW | 5PSQ-100 |
| ANALYSIS OF HIP PROSTHESES OVER A YEAR | 5PSQ-101 | |
| SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY | 5PSQ-102 |
| PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS | 5PSQ-103 |
| ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT | 5PSQ-104 |
| DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE | 5PSQ-105 |
| SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT | 5PSQ-106 |
| SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE | 5PSQ-107 |
| COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW | 5PSQ-108 |
| RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW? | 5PSQ-109 |
| IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS | 5PSQ-110 | |
| MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL | 5PSQ-111 |
| RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER | 5PSQ-112 |
| REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS | 5PSQ-113 |
| PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB | 5PSQ-114 |
| DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE. | 5PSQ-115 |
| PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS. | 5PSQ-116 |
| EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE | 5PSQ-117 |
| PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY | 5PSQ-118 |
| A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED | 5PSQ-119 |
| ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION | 5PSQ-120 |
| CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT | 5PSQ-121 |
| COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA | 5PSQ-122 |
| IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV | 5PSQ-123 |
| EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS | 5PSQ-124 |
| BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY? | 5PSQ-125 |
| EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA | 5PSQ-126 |
| PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW | 5PSQ-127 |
| THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION. | 5PSQ-128 |
| SWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE | 5PSQ-129 |
| OFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT | 5PSQ-130 |
| LETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT | 5PSQ-131 |
| PHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY | 5PSQ-132 |
| PHARMACISTS – GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY | 5PSQ-133 |
| UNIT DOSE IN A CYBERATTACK SCENARIO | 5PSQ-134 |
| HAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION? | 5PSQ-135 |
| ANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS | 5PSQ-136 |
| ANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES | 5PSQ-137 |
| CHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION | 5PSQ-138 |
| USING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs) | 5PSQ-139 |
| FREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs) | 5PSQ-140 |
| FALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES. | 5PSQ-141 |
| EVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT | 5PSQ-142 |
| THE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE’S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB | 5PSQ-143 |
| ELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY | 5PSQ-144 |
| A PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL | 5PSQ-145 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT | 5PSQ-001 |
| PHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS) | 5PSQ-002 |
| PERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT | 5PSQ-003 |
| EPCLUSA RELATED SLEEPINESS: A CASE REPORT | 5PSQ-004 |
| ANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA | 5PSQ-005 |
| IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: A 7-MONTHS ANALYSIS | 5PSQ-006 |
| IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: WHAT’S NEW AND WHAT’S LEFT? | 5PSQ-007 |
| A DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES. | 5PSQ-008 |
| EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS | 5PSQ-009 |
| DIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE | 5PSQ-010 |
| PHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION | 5PSQ-011 |
| CASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS – 24 MONTHS OF FOLLOW-UP | 5PSQ-012 |
| PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE. | 5PSQ-013 |
| IMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL – TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY) | 5PSQ-014 |
| PERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM | 5PSQ-015 |
| HUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS – A STUDY BASED ON INCIDENT REPORTS | 5PSQ-016 |
| IMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN. | 5PSQ-017 |
| PRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY? | 5PSQ-018 |
| ANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL | 5PSQ-019 |
| ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT | 5PSQ-020 | |
| AUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING | 5PSQ-021 |
| ANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE | 5PSQ-022 |
| SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT | 5PSQ-023 |
| HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING | 5PSQ-024 |
| IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE. | 5PSQ-025 |
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS | 5PSQ-026 |
| APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA | 5PSQ-027 |
| CDK 4/6 INHIBITORS – ANALYSIS OF POTENTIAL DRUG INTERACTIONS | 5PSQ-028 |
| PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME | 5PSQ-029 |
| SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA | 5PSQ-030 |
| ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED | 5PSQ-031 |
| PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM | 5PSQ-032 |
| ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B | 5PSQ-033 |
| FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING | 5PSQ-034 |
| MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA | 5PSQ-035 |
| MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA | 5PSQ-036 |
| IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION | 5PSQ-037 |
| DRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS | 5PSQ-038 |
| RAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE. | 5PSQ-039 |
| ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE | 5PSQ-040 | |
| STERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT | 5PSQ-041 |
| PREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA. | 5PSQ-042 |
| UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST | 5PSQ-043 | |
| REAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS | 5PSQ-044 |
| IMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS | 5PSQ-045 |
| FMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST | 5PSQ-046 |
| PRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY | 5PSQ-047 |
| WHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS. | 5PSQ-048 |
| ASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL | 5PSQ-049 |
| ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE | 5PSQ-050 |
| PARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT | 5PSQ-051 |
| CHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS | 5PSQ-052 |
| DESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX | 5PSQ-053 |
| ASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI) | 5PSQ-054 |
| SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR) | 5PSQ-055 | |
| HETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE | 5PSQ-056 |
| EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE | 5PSQ-057 |
| MANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE | 5PSQ-058 |
| REAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT | 5PSQ-059 |
| GLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL. | 5PSQ-060 |
| NEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS | 5PSQ-061 |
| REVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS. | 5PSQ-062 |
| A CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS | 5PSQ-063 |
| CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT | 5PSQ-064 |
| BE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE | 5PSQ-065 |
| ADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE | 5PSQ-066 |
| TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES | 5PSQ-067 | |
| DIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS | 5PSQ-068 |
| ANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES. | 5PSQ-069 |
| PHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT | 5PSQ-070 |
| ANALYSIS OF MEDICATION PROVIDED BY PATIENTS | 5PSQ-071 |
| ANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY. | 5PSQ-072 |
| IS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE | 5PSQ-073 |
| INTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL | 5PSQ-074 |
| PROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT | 5PSQ-075 |
| PATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION | 5PSQ-076 |
| CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS – REAL-WORLD DATA ANALYSIS | 5PSQ-077 | |
| ANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-19 | 5PSQ-078 |
| FONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT. | 5PSQ-079 |
| IDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT | 5PSQ-080 |
| ASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC | 5PSQ-081 |
| GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS. | 5PSQ-082 | |
| FOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY | 5PSQ-083 |
| ASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES | 5PSQ-084 |
| MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM | 5PSQ-085 |
| ANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME | 5PSQ-086 |
| EVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES | 5PSQ-087 |
| EXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL | 5PSQ-088 |
| CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS? | 5PSQ-089 | |
| STUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM. | 5PSQ-090 |
| TRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION | 5PSQ-091 |
| PHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT | 5PSQ-092 |
| PHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM | 5PSQ-093 |
| TOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE | 5PSQ-094 |
| CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY | 5PSQ-095 | |
| A PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT. | 5PSQ-096 |
| HEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION | 5PSQ-097 |
| SAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES | 5PSQ-098 |
| ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL | 5PSQ-099 |
| UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW | 5PSQ-100 |
| ANALYSIS OF HIP PROSTHESES OVER A YEAR | 5PSQ-101 | |
| SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY | 5PSQ-102 |
| PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS | 5PSQ-103 |
| ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT | 5PSQ-104 |
| DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE | 5PSQ-105 |
| SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT | 5PSQ-106 |
| SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE | 5PSQ-107 |
| COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW | 5PSQ-108 |
| RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW? | 5PSQ-109 |
| IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS | 5PSQ-110 | |
| MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL | 5PSQ-111 |
| RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER | 5PSQ-112 |
| REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS | 5PSQ-113 |
| PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB | 5PSQ-114 |
| DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE. | 5PSQ-115 |
| PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS. | 5PSQ-116 |
| EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE | 5PSQ-117 |
| PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY | 5PSQ-118 |
| A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED | 5PSQ-119 |
| ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION | 5PSQ-120 |
| CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT | 5PSQ-121 |
| COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA | 5PSQ-122 |
| IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV | 5PSQ-123 |
| EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS | 5PSQ-124 |
| BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY? | 5PSQ-125 |
| EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA | 5PSQ-126 |
| PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW | 5PSQ-127 |
| THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION. | 5PSQ-128 |
| SWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE | 5PSQ-129 |
| OFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT | 5PSQ-130 |
| LETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT | 5PSQ-131 |
| PHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY | 5PSQ-132 |
| PHARMACISTS – GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY | 5PSQ-133 |
| UNIT DOSE IN A CYBERATTACK SCENARIO | 5PSQ-134 |
| HAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION? | 5PSQ-135 |
| ANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS | 5PSQ-136 |
| ANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES | 5PSQ-137 |
| CHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION | 5PSQ-138 |
| USING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs) | 5PSQ-139 |
| FREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs) | 5PSQ-140 |
| FALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES. | 5PSQ-141 |
| EVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT | 5PSQ-142 |
| THE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE’S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB | 5PSQ-143 |
| ELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY | 5PSQ-144 |
| A PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL | 5PSQ-145 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| The appropriateness review FOR HOSPITAL MEDICATION ORDERS IN FINLAND | NP-01 |
| Usage of falls-risk-increasing drugs among patients with high risk of falls in the nursing ward of Tartu University Hospital | NP-02 |
| From basic to advanced computerized IV to oral switch for paracetamol and antibiotics: an interrupted time series analysis | NP-03 |
| MONITORING OF GRAM-NEGATIVE (G-) MULTIDRUG RESISTANT (MDR) PATIENS AT POLICLINICO UMBERTO I OF ROME WITH THE AIM OF CONTROLLING HEALTHCARE ASSOCIATED INFECTIONS, COUNTERACTING THE PHENOMENON OF ANTIMICROBIAL RESISTANCE AND… | NP-04 |
| INTRAVESICAL EPIRUBICIN ADMINISTRATION IN A UROLOGY DEPARTMENT | NP-05 |
| RELATIONSHIP BETWEEN SERUM VEDOLIZUMAB CONCENTRATIONS IN INDUCTION PHASE AND EARLY AND SUSTAINED RESPONSE ON PATIENTS WITH ULCERATIVE COLITIS | NP-06 |
| Integrating pharmacogenetic information into medication reviews – an interprofessional challenge | NP-08 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS | 1ISG-003 |
| ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA | 1ISG-004 |
| ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER | 1ISG-006 | |
| ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL? | 1ISG-007 |
| OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA | 1ISG-008 |
| IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY | 1ISG-009 |
| ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB | 1ISG-012 |
| Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation | 1ISG-013 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| HOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS | 2SPD-001 |
| TELEPHARMACY IN ONCO-HEMATOLOGIC PATIENTS: A SEVEN MONTH EXPERIENCE | 2SPD-003 |
| SIGNIFICANT DISCONTINUATION RATES IN PATIENTS INITIATING OR SWITCHING FROM CT-P13: A RETROSPECTIVE COHORT STUDY IN A UNIVERSITY HOSPITAL | 2SPD-005 |
| DEVELOPMENT OF A PRIORITATION PROTOCOL FOR THE USE OF IMMUNOGLBULINS IN VIEW OF THE GLOBAL SUPPLY PROBLEM | 2SPD-006 |
| NETWORK META-ANALYSIS OF IMMUNOTHERAPIES IN UNTREATED ADVANCED OR METASTARIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA | 2SPD-008 |
| RIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY | 2SPD-011 |
| IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE | 2SPD-012 |
| INCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT | 2SPD-013 |
| APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE | 2SPD-014 |
| LOGISTICS AUTOMATION AND PROCESS REENGINEERING: IMPACT ON INTER-HOSPITAL LOAN MANAGEMENT | 2SPD-015 |
| APPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT | 2SPD-016 |
| ANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES | 2SPD-017 |
| INVENTORY MANAGEMENT DURING THE COVID-19 PANDEMIC: OUR CASE FOR THE THIRD WAVE | 2SPD-019 |
| INTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION | 2SPD-020 |
| ASSESSMENT OF FORECAST ACCURACY FOR CONTRACTUAL PURCHASES | 2SPD-021 |
| RELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES | 2SPD-022 |
| CHOOSING THE RIGHT FORECASTING METHOD: WHICH PRACTICE IS BEST FOR OUR CASE? | 2SPD-023 |
| RETROSPECTIVE EVALUATION OF THE SAFETY STOCK LEVEL DETERMINED FOR THE PANDEMIC IN TERMS OF SERVICE LEVEL | 2SPD-024 |
| ACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA | 2SPD-025 |
| Medication storage temperatures inside emergency vehicles A pilot study in a temperate climate country | 2SPD-027 |
| STABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS | 2SPD-029 |
| How to assess the impact of medicines shortages in the European Union? | 2SPD-030 |
| THE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES | 2SPD-031 |
| DRUG EXCHANGE NETWORK | 2SPD-032 |
| Making the case for Prefilled Syringes (PFS): Development and utilisation of an economic model | 2SPD-033 |
| METHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW | 2SPD-034 |
| COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER | 2SPD-035 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| CHOLESTEROL 2%/SIMVASTATIN 1% OINTMENT FOR THE TREATMENT OF POROKERATOSIS PTYCHOTROPICA: A CASE REPORT | 3PC-001 |
| GLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT? | 3PC-002 |
| SODIUM THIOSULPHATE GEL 25% FOR THE TREATMENT OF CALCIPHYLAXIS | 3PC-003 | |
| INSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION | 3PC-004 |
| SELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION | 3PC-005 |
| EVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST | 3PC-006 |
| TIMES AND ERRORS FOR DISPENSING NARCOTICS DRUGS IN AUTOMATED SYSTEM VERSUS MANUAL SYSTEM | 3PC-008 |
| STANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL | 3PC-009 |
| Assessment of Chemfort (OnGuard, US) Syringe Adaptor Lock Fitted With Luer Lock Syringes to Container Integrity Standards (NHS, UK) Supporting Dose Banding of Cytotoxic Drugs | 3PC-010 |
| STUDY OF THE CONTAINERCONTENT INTERACTION BETWEEN ETOPOPHOS POLYVINYL CHLORIDE (PVC) PERFUSION | 3PC-011 |
| IMPACT OF PRELIMINARY WIPING OF EQUIPMENT INTRODUCED INTO A CLEANROOM ON THE CONTROL OF THE ENVIRONMENT | 3PC-012 |
| PHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION? | 3PC-013 |
| EVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY | 3PC-014 |
| VANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS | 3PC-016 |
| Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days | 3PC-017 |
| COMPATIBILITY AND 30-DAY STABILITY OF FOUR INTRAVENOUS MIXTURES FOR MULTIMODAL ANALGESIA | 3PC-018 |
| EVALUATION OF THE IMPACT OF MACHINE-AIDED DEBLISTERING IN UNIT DOSE BLISTER PRODUCTION ON THE FUNCTIONALITY OF TABLET COATING | 3PC-019 |
| CHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE | 3PC-020 |
| DESIGN AND ELABORATION OF METRONIDAZOLE 1% TOPICAL SOLUTION FOR TREATMENT OF ULCERS INFECTED BY ANAEROBIC BACTERIA | 3PC-021 |
| PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA | 3PC-022 | |
| Investigation of Leachable Compounds In water for injection used in hospital pharmacy | 3PC-023 |
| IMPACT OF PH MODIFICATION ON THE AGGREGATION OF NIVOLUMAB (OPDIVO) IN CLINICAL SOLUTIONS AT 1 AND 5 MG/ML MEASURED BY DYNAMIC LIGHT SCATTERING (DLS) AND SIZEEXCLUSION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-DIODE ARRAY DETECTION (SE/HPLC-DAD) | 3PC-024 | |
| Rainer Trittler, Brigitte Altmann, Manuel Garcia-Käufer, Richard Gminski, Martin J. Hug | 3PC-026 |
| DIGITALIZATION SUPPORT SYSTEM FOR INTRAVENOUS MIXTURES ELABORATION IN A BIOLOGICAL SAFETY CABINET | 3PC-027 |
| PHARMACEUTICAL INTERVENTIONS IN PAEDIATRIC PARENTERAL NUTRITION | 3PC-028 |
| STUDY OF PSMA11-68GA ADSORPTION ON MEDICAL DEVICES USED FOR RADIOSYNTHESIS AND MEDIA FILL TEST | 3PC-029 |
| Different substrates for orodispersible films: You have the choice! | 3PC-030 |
| PHYSICOCHEMICAL STABILITY OF helen.linxweiler@unimedizin-mainz.de DILUTED ‘THIOTEPA RIEMSER’ INFUSION SOLUTIONS IN PREFILLED 5% GLUCOSE INFUSION BAGS | 3PC-031 |
| Optimising Analgosedation in the Intensive Care Unit during the SARS-COV-2 Pandemic | 3PC-032 |
| Y-site Compatibility of Intravenous Nefopam with Medications Commonly Used in Intensive Care Units | 3PC-033 |
| DEVELOPMENT AND VALIDATION OF A METHOD FOR THE DETERMINATION OF VANCOMYCIN EYE DROPS BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY | 3PC-034 |
| Minimising Waste In Oncology | 3PC-035 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| COVID-19 HOSPITAL VACCINATION CENTER: PATIENT AND NURSE SATISFACTION | 4CPS-002 |
| OUTPATIENT-REPORTED EXPERIENCE IN HOSPITAL PHARMACY AMBULATORY CARE DURING THE COVID19 PANDEMIC | 4CPS-003 | |
| IMPACT OF THE SARS-COV PANDEMIC ON THE TRAINING OF HOSPITAL PHARMACY RESIDENTS | 4CPS-004 |
| Evaluating pharmaceutical logistics automated technologies in the hospital setting: a Health Technology Assessment (HTA) approach | 4CPS-005 | |
| EVALUATION STUDY OF THE CHAGE IN ADMINISTRATION TIMING OF FIXED COMBINATION: NETUPITANT AND PALONOSETRON IN ONCOHEMATOLOGIC PATIENTS WITH HIGH DOSES OF CARBOPLATIN | 4CPS-006 |
| The role of the pharmacist in the management of Intravenous fluids & electrolytes in adult patients | 4CPS-008 |
| ASSESSMENT OF KNOWLEDGE, ATTITUDES AND PRACTICES REGARDING ANTIBIOTIC RECONSTITUTION AMONG HEALTHCARE PROFESSIONALS IN 12 SOUTHEASTERN EUROPEAN HOSPITALS: A MULTICENTRE CROSS-SECTIONAL STUDY | 4CPS-011 |
| MERGING THE MEDICATION RECONCILIATION AND THE HOSPITALIZATION REPORT TO FORM THE LIAISON LETTER IN A DEPARTMENT OF OTOLARYNGOLOGY | 4CPS-013 |
| CLINICAL RELEVANCE OF PHARMACISTS’ INTERVENTIONS IN THE ACUTE WARD | 4CPS-014 |
| SATISFACTION AND INDIRECT IMPACT OF AN OUTPATIENTS’ TELEPHARMACY PROGRAMME | 4CPS-015 |
| Factors influencing the attitudes and opinions of Czech physicians and citizens toward influenza vaccination in Czech pharmacies | 4CPS-016 |
| THE DECISION-MAKING PROCESS IN HEALTH POLICY IMPACTS CLINICAL PRACTICES: A QUALITATIVE STUDY | 4CPS-017 |
| Perceptions of young people regarding pharmaceutical care provided by pharmacists | 4CPS-018 |
| REACTOGENICITY OF THE BNT162B2 (PFIZERBIONTECH) MRNA VACCINE AGAINST COVID-19 IN TERTIARY HOSPITAL WORKERS | 4CPS-019 |
| COMPARISON OF DEPRESCRIBING STRATEGIES: LESSCHRON CRITERIA VERSUS THE GOOD PALLIATIVEGERIATRIC ALGORITHM IN A NURSING HOME | 4CPS-020 |
| POST-STERNOTOMY MEDIASTINITIS: A MEDICOECONOMIC STUDY COMPARING TWO PREVENTIVE STRATEGIES IN CARDIAC SURGERY | 4CPS-021 |
| To vaccinate or not to vaccinate : Impact of a public health action on vaccine hesitancy | 4CPS-022 |
| INDIVIDUALIZATION OF TREATMENT WITH TOCILIZUMAB IN GRAVES ORBITHOPATHY | 4CPS-023 |
| PHARMACEUTICAL INTERVIEWS DEDICATED TO VACCINATION: WHAT ROLE FOR THE CLINICAL PHARMACIST IN MONITORING THE VACCINATION COVERAGE OF AT-RISK PATIENTS ? | 4CPS-024 |
| Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab | 4CPS-025 |
| OPTIMISATION OF DIRECT ORAL ANTICOAGULANT TREATMENTS: ANALYSIS OF PRESCRIPTIONS AND PHARMACEUTICAL INTERVIEWS (PI) | 4CPS-026 |
| DESENSITISATION PROTOCOL FOR LIPOSOMAL AMPHOTHERICIN B: A CASE REPORT | 4CPS-027 |
| EFFECTIVENESS AND SAFETY OF CENOBAMATE: EXPERIENCE IN A THIRD-LEVEL HOSPITAL | 4CPS-028 |
| PEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO | 4CPS-029 |
| SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA IN AN INTENSIVE CARE UNIT | 4CPS-030 |
| EFFICACY AND SAFETY OF HIGH-DOSE TWICE WEEKLY SEBELIPASE ALFA IN SEVERE-ONSET WOLMAN DISEASE: A CASE REPORT | 4CPS-031 |
| Medication errors in prescribing antithrombotics for patients admitted to the hospital in the weekend. A pilot-study | 4CPS-032 |
| Development and evaluation of an amitriptyline topical form for the treatment of cancer-related neuropathy | 4CPS-033 |
| DEPRESCRIBING ORAL IRON IN ELDERLY PATIENTS: EXPERIENCE FROM A NURSING HOME ASSOCIATED WITH A THIRD LEVEL HOSPITAL | 4CPS-034 |
| PHARMACIST-LED MEDICATION RECONCILIATION AT DISCHARGE SHALL NOT BE SUFFICIENT TO REDUCE UNPLANNED HEALTHCARE UTILIZATION: HEAR THE PATIENT EXPERIENCE! | 4CPS-035 |
| IS OUR PROTOCOL FOR THE USE OF TOCILIZUMAB IN COVID PATIENTS ADEQUATE? | 4CPS-036 |
| The 5P-study: Patient and healthcare Provider Perspectives on Potential Preventability of hospital admission for acute exacerbations of Chronic Obstructive Pulmonary Disease | 4CPS-037 |
| Intrapleural colistin for pleural empyema caused by extensively drug-resistant Pseudomonas aeruginosa: A case report | 4CPS-038 |
| EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE TREATMENT OF MIGRAINE | 4CPS-039 |
| INTERINDIVIDUAL VARIABILITY OF LINEZOLID IN CRITICALLY ILL PATIENTS | 4CPS-040 |
| SACUBITRIL/ VALSARTAN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE | 4CPS-041 |
| PHARMACOKINETIC MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS | 4CPS-042 |
| EFFECTIVENESS, SAFETY AND ADHERENCE OF GUSELKUMAB IN MODERATE TO SEVERE PSORIASIS | 4CPS-043 |
| PATIENTS’ PERCEPTIONS OF HEALTHCARE ASSOCIATED-INFECTIONS AND USE OF ANTIBIOTICS IN SURGICAL CONTEXT | 4CPS-044 |
| HEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY | 4CPS-045 |
| CARDIOVASCULAR RISK OF HIV PATIENTS | 4CPS-046 |
| IMPROVING SAFETY IN THE USE OF MONOCLONAL ANTIBODIES IN PATIENTS WITH MIGRAINE: AN INTERDISCIPLINARY STUDY | 4CPS-048 |
| MANAGEMENT OF PAN-RESISTANT STENOTROPHOMONAS MALTOPHILIA | 4CPS-049 |
| USE OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE IN A TERTIARY HOSPITAL: HEALTH RESULTS | 4CPS-050 |
| PHARMACOKINETICS ALTERATIONS IN TWO CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL | 4CPS-051 |
| GALCANEZUMAB IN PROPHYLAXIS OF REFRACTORY HIGH-FREQUENCY EPISODIC MIGRAINE IN CLINICAL PRACTICE | 4CPS-053 |
| ANALYSIS OF REAL-WORLD DATA FOR ERENUMAB UTILISATION AND PATIENT-RELATED OUTCOMES | 4CPS-054 |
| SUCCESSFUL SOFOSBUVIR/VELPATASVIR TREATMENT IN A HEPATITIS C PATIENT RECEIVING CHRONIC ANTIEPILEPTIC THERAPY: A CASE REPORT | 4CPS-055 |
| POLYPHARMACY AND POTENTIALLY INAPPROPIATE MEDICATIONS IN OLDER PEOPLE LIVING WITH HIV | 4CPS-056 |
| DISCONTINUATION OF PROTON PUMP INHIBITORS DURING HOSPITALISATION: A RANDOMISED CONTROLLED TRIAL | 4CPS-057 |
| REAL-WORLD EXPERIENCE WITH PROLONGED TEDIZOLID TREATMENT: EFFECTIVENESS AND SAFETY | 4CPS-058 |
| CASE REPORT OF SEVERE HYPERBILIRRUBINEMIA IN A PATIENT CARRYING POLYMORPHISMS IN CES1P1, CDA, SLC22A7 AND ENOSF1 TREATED WITH FLUOROPYRIMIDINES | 4CPS-059 |
| INFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER | 4CPS-060 |
| IMPACT OF PHARMACOGENETICS ON THE TOXICITY OF HIGH-DOSE METHOTREXATE IN A PAEDIATRIC POPULATION | 4CPS-061 |
| RITUXIMAB PHARMACOKINETICS CHARACTERIZATION IN PLASMA AND URINE IN A PATIENT WITH NEPHOTIC SYNDROME | 4CPS-062 |
| ERENUMAB VERSUS GALCANEZUMAB, EFFECTIVENESS IN REAL-LIFE EXPERIENCE | 4CPS-063 |
| QUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE | 4CPS-064 |
| SAFETY OF BEVACIZUMAB BIOSIMILAR IN CLINICAL PRACTICE IN NEW AND SWITCHED TREATMENTS | 4CPS-065 |
| PHARMACIST INTERVENTIONS IN SEQUENTIAL ANTIMICROBIAL THERAPY INSIDE AN ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP) | 4CPS-067 |
| IMPACT OF PHARMACOGENETICS IN SEVERE ALLERGIC ASTHMA PATIENTS TREATED WITH OMALIZUMAB | 4CPS-068 |
| INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER | 4CPS-069 |
| STUDY OF CARDIOVASCULAR TOXICITY ASSOCIATED WITH IBRUTINIB TREATMENT | 4CPS-070 |
| CYP27B1 GENETIC VARIANTS’ INFLUENCE IN NEPHROTOXICITY DUE TO PLATINUMBASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER | 4CPS-071 |
| BEZLOTOXUMAB FOR THE PREVENTION OF CLOSTRIDIOIDES DIFFICILE RECURRENCE: STUDY IN THE REAL WORLD | 4CPS-072 |
| DESENSITISATION TO IBRUTINIB IN A PATIENT WITH SERIOUS LATE REACTION: A CASE REPORT | 4CPS-073 |
| EVALUATION OF THE COST OF MANAGING ADVERSE EVENTS RELATED TO CYTOTOXIC DRUGS IN CHILDREN | 4CPS-075 |
| GENETICVARIANTSAFFECTINGBISOPROLOL RESPONSEINCARDIOVASCULARDISEASES | 4CPS-077 |
| MOTIVATIONAL INTERVIEWING IN CLINICAL PHARMACIST INTERVENTIONS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS | 4CPS-078 |
| ANALYSIS OF CURRENT RESEARCH IN WEAREABLES : TOWARD A MORE DIGITAL HEALTH | 4CPS-079 |
| EFFICACY AND SAFETY OF THE CONTINUOUS INFUSION OF VANCOMYCIN IN PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW | 4CPS-080 | |
| SUBCUTANEOUS FUROSEMIDE INFUSION USING ELASTOMERIC INFUSION PUMPS IN A TERTIARY HOSPITAL | 4CPS-081 |
| ENVIRONMENTAL POLLUTION WITH QUINOLONES IN SPAIN | 4CPS-082 | |
| Cost-effectiveness analysis of adalimumab and its clinical alternatives in immunemediated inflammatory diseases in Spain | 4CPS-083 |
| STABILITY OF MEROPENEM AND PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION FOR HOME ADMINISTRATION | 4CPS-085 |
| Inhaled sedation with halogenated agents in the Intensive Care Unit: A literature mini-review | 4CPS-086 |
| THE USE OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW | 4CPS-087 |
| INDIRECT COMPARISON OF NIVOLUMAB, PEMBROLIZUMAB AND CAMRELIZUMAB IN PATIENTS WITH UNRESECTABLE AND/OR ADVANCED SQUAMOUS CELL CARCINOMA OF ESOPHAGUS IN SECOND-LINE SETTING | 4CPS-088 |
| RISANKIZUMAB IN REFRACTORY HIDRADENITIS SUPPURATIVA TO ANTI-TNFa A CASE REPORT | 4CPS-089 |
| EFFICACY AND SAFETY OF PANGENOTYPS TREATMENTS IN HCV PATIENTS | 4CPS-090 |
| ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO HIGH-RISK-DRUGS IN THE EMERGENCY DEPARTMENT | 4CPS-091 |
| BIOLOGICAL THERAPIES FOR THE TREATMENT OF PSORIASIS: EFFECTIVENESS, SAFETY AND ECONOMIC IMPACT OF OPTIMISATION STRATEGIES | 4CPS-092 |
| DRUG-INDUCED SOMNOLENCE IN FRAILTY PATIENTS ATTENDED IN AN EMERGENCY DEPARTMENT | 4CPS-093 |
| APPROPRIATENESS OF EMPIRICAL ANTIBIOTIC THERAPY FOR CERVICITIS AND URETHRITIS PRESCRIBED AT THE EMERGENCY DEPARTMENT | 4CPS-095 |
| CLINICALLY RELEVANT DRUG-DRUG INTERACTION EVENTS IN PATIENTS WITH ABIRATERONE, ENZALUTAMIDE OR APALUTAMIDE TREATMENT | 4CPS-099 |
| INTRADIALYTIC PARENTERAL NUTRITION EFFECTS ON ALBUMIN LEVELS IN MALNOURISHED HAEMODIALYSIS PATIENTS | 4CPS-100 |
| BIOLOGIC AGENTS IN RHEUMATOLOGICAL DISEASES: IMPACT OF ‘TREAT TO TARGET’ IN CLINICAL PRACTICE | 4CPS-101 |
| Drug-related hospital admissions in older adults: comparison of the Naranjo algorithm and an adjusted version of the Kramer algorithm | 4CPS-102 |
| IMPROVING MEDICATION RECONCILIATION REPORTS: EVALUATION THROUGH QUALITY AUDITS | 4CPS-103 |
| PERSISTENCE WITH DISEASE-MODIFYING THERAPY IN MULTIPLE SCLEROSIS PATIENTS | 4CPS-104 |
| CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HIV INFECTION WITH ANTIRETROVIRAL TREATMENT | 4CPS-105 |
| SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER | 4CPS-106 |
| IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE | 4CPS-107 |
| BIOMARKERS EVOLUTION IN PATIENTS WITH SARSCOV-2 PNEUMONIA TREATED WITH BARICITINIB | 4CPS-108 |
| DESCRIPTIVE ANALYSIS OF PATIENTS CO-INFECTED WITH HIV AND HEPATITIS C VIRUS (HCV) TREATED WITH ANTIVIRALS FOR HCV AND ITS EFFICACY IN A PRISON FROM 2002 TO 2020 | 4CPS-109 |
| INITIAL EXPERIENCE OF THE USE OF CEFIDEROCOL FOR MULTIDRUG RESISTANT INFECTIONS IN A UNIVERSITY HOSPITAL | 4CPS-110 |
| RUXOLITINIB FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE IN PAEDIATRIC PATIENTS | 4CPS-111 |
| VORICONAZOLE THERAPEUTIC DRUG MONITORING: RELATIONSHIP WITH LIVER TOXICITY | 4CPS-112 |
| REAL-LIFE DATA ON THE USE OF ABIRATERONE/ ENZALUTAMIDE IN CASTRATION-RESISTANT PROSTATE CANCER | 4CPS-113 |
| INTEGRATION OF A PHARMACIST INTO A GERIATRIC DEPARTMENT | 4CPS-114 |
| NABPACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN METASTATIC PANCREATIC CANCER: REAL WORLD DATA EXPERIENCE | 4CPS-115 |
| ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE | 4CPS-116 | |
| APPROPRIATENESS OF ANTIBIOTIC PRESCRIPTIONS IN A LONG-TERM CARE FACILITY | 4CPS-117 |
| REAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA | 4CPS-119 |
| ADVERSE DRUG REACTION (ADR) NOTICATIONS’ IMPACT ON PATIENTS FOLLOWED AT AN AMBULATORY CARE PHARMACY UNIT | 4CPS-120 |
| CLINICAL PHARMACIST INTERVENTIONS IN THE EMERGENCY DEPARTMENT AND THEIR IMPACT ON PREVENTABLE ADVERSE DRUG EVENTS | 4CPS-121 |
| OVERVIEW OF THE IMPACT OF PENICILLIN ALLERGY LABELS ON ANTIBIOTIC USE IN THE EMERGENCY DEPARTMENT | 4CPS-122 |
| PERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS | 4CPS-123 |
| COST OPTIMISATION PLAN IN IMMUNOTHERAPY | 4CPS-124 |
| SINGLE-AGENT BEVACIZUMAB IN OFF-LABEL TREATMENT OF RECURRENT OR REFRACTORY GLIOMA | 4CPS-125 |
| REAL-WORLD PERSISTENCE WITH FAMPRIDINE AMONG MULTIPLE SCLEROSIS PATIENTS | 4CPS-126 |
| THERAPEUTIC DRUG MONITORING WITH BIOLOGICAL DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | 4CPS-127 |
| ADJUST DOSES OF ANTIBIOTICS IN PATIENTS WITH RENAL INSUFFICIENCY | 4CPS-129 |
| Analysis of the Different Cardioversion Strategies in the Emergency Department in a Secondary Hospital | 4CPS-130 |
| SWITCHING AND DISCONTINUATION OF DISEASE-MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS: EXPERIENCE IN AN UNIVERSITY HOSPITAL | 4CPS-131 |
| ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT | 4CPS-133 |
| OPTIMIZATION OF DENOSUMAB PRESCRIPTION IN OSTEOPOROSIS PATIENTS | 4CPS-134 |
| PERSISTENCE OF FIRST-LINE BIOLOGICAL THERAPY IN PATIENTS WITH CROHN’S DISEASE | 4CPS-136 |
| Prospective analysis of clinical pharmacist interventions for QT drug-drug interactions alongside clinical decision support | 4CPS-137 |
| THERAPEUTIC DRUG MONITORING OF INTRAVENOUSBUSULFANINPAEDIATRICPATIENTS | 4CPS-138 |
| ANTIMICROBIAL STEWARDSHIP PROGRAM IN ONCOLOGY PATIENTS THROUGH A MULTIDISCIPLINARY TEAM | 4CPS-140 | |
| ASSESSMENT OF TEDIZOLID FOR USE IN GRAM-POSITIVE BACTERIAL INFECTIONS BACKGROUND: REAL WORLD DATA | 4CPS-141 |
| EFFECTIVENESS AND SAFETY OF ATEZOLIZUMAB IN METASTATIC UROTHELIAL CARCINOMA | 4CPS-142 |
| EFFECTIVENESS AND SAFETY OF BARICITINIB AND TOFACITINIB IN REUMATOID ARTHRITIS IN CLINICAL PRACTICE | 4CPS-145 |
| Development and validation of a rapid High Performance Liquid Cromatography method (HPLC) for the determination of triazoles in human plasma | 4CPS-146 |
| EXPERIENCE OF USE OF BIOLOGICAL ANTIMIGRAINE TREATMENTS IN CLINICAL PRACTICE | 4CPS-147 |
| Use of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients | 4CPS-148 |
| HOSPITAL AT HOME COVID UNIT: MULTIDISCIPLINARY STRATEGIES | 4CPS-149 |
| Ability to assess acute kidney injury in patients admitted to hospital | 4CPS-150 |
| CHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING | 4CPS-152 |
| STEVENS–JOHNSON SYNDROME IN A PREGNANT WOMAN CAUSED BY PYRIMETHAMINE AND SULFADIZINE | 4CPS-154 |
| APPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT | 4CPS-155 |
| ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A GENERAL SURGERY SERVICE: ROLE OF THE PHARMACIST | 4CPS-156 |
| IMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES | 4CPS-157 |
| BUDGETARY IMPACT OF PCSK9I DOSES REGIMEN OPTIMISATION | 4CPS-161 |
| CYTOKINE RELEASE SYNDROME IN ONCOHAEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB | 4CPS-162 |
| EARLY EXPERIENCES IN SWITCHING BETWEEN MONOCLONAL ANTIBODIES IN CHRONIC MIGRAINE PREVENTIVE THERAPY | 4CPS-163 |
| DURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS | 4CPS-164 |
| HAS COVID AFFECTED THE TREATMENT OF ONCOLOGY PATIENTS?: A DESCRIPTIVE STUDY OF TREATMENTS FROM 2019 TO 2021 | 4CPS-165 |
| ASSOCIATION BETWEEN IMMUNE-RELATED EFFECTS AND EFFECTIVENESS OF FIRST-LINE PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER | 4CPS-166 |
| SODIUM AND MAGNESIUM ALTERATIONS IN THE CRITICAL PATIENT WITH SARS-CoV-2 AND PARENTERAL NUTRITION | 4CPS-167 |
| Review of new biomarkers that predict the pharmacokinetics of biologic drugs in inflammatory bowel disease | 4CPS-170 |
| EFFECT OF LIPIDIC COMPOSITION OF PARENTERAL NUTRITION ON THE DEVELOPMENT OF HYPERTRIGLYCERIDAEMIA AND CHOLESTASIS | 4CPS-171 |
| POSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL | 4CPS-172 |
| PHARMACEUTICAL INTERVENTION IN BROAD-SPECTRUM ANTIBIOTIC PRESCRIPTION IN HOSPITALIZED PATIENTS | 4CPS-173 |
| EFFECTIVENESS OF OBETICOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS E | 4CPS-174 | |
| MEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS | 4CPS-175 |
| ORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY | 4CPS-176 |
| A QUALITATIVE STUDY ON PHARMACIST PRESCRIBING FOR PATIENTS WITH CHRONIC KIDNEY DISEASE | 4CPS-177 |
| THERAPEUTIC DRUG MONITORINGOF GENTAMICIN AFTER PRE-DIALYSIS ADMINISTRATION | 4CPS-178 |
| “Description and Follow-up of the Use of Emtricitabin/ Tenofovir for HIV Pre-Exposure Prophylaxis | 4CPS-179 |
| INCREASE IN THE PRESCRIPTION OF BENZODIAZEPINES IN THE CONTEXT OF THE SARSCOV-2 PANDEMIC | 4CPS-182 |
| Prevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device | 4CPS-183 |
| A toll for Hospital Pharmacist Interventions optimization | 4CPS-185 |
| 2020 ANTIMICROBIAL CONSUMPTION INDICATORS: ANALYSIS COMPARED WITH PREVIOUS YEARS | 4CPS-186 |
| Pharmacist-clinician Collaborative Study for Prospective Identification of Drug Interactions on HIV Patients | 4CPS-187 |
| TELEPHARMACY: A PILOT EXPERIENCE IN TIMES OF COVID-19 IN A TERTIARY HOSPITAL | 4CPS-190 |
| SWITCH TO BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA | 4CPS-191 |
| IMPACT OF THE SARS-COV-2 PANDEMIC ON THE USE OF ANTIFUNGALS IN AN INTENSIVE CARE UNIT IN A THIRD-LEVEL HOSPITAL | 4CPS-192 |
| Selection of clinical rules for the screening of high-risk situations in paediatric medicine | 4CPS-193 |
| CLINICAL IMPACT OF A PHARMACIST-LED DISCHARGE MEDICATION REVIEW SERVICE: AN ANALYSIS OF PREVALENCE AND ACCEPTANCE OF INTERVENTIONS | 4CPS-194 |
| Medication-related readmissions: documentation and communication to the next healthcare providers and patients | 4CPS-195 |
| Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs | 4CPS-197 |
| THE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY | 4CPS-198 |
| EVALUATION OF FREMANEZUMAB RESPONSE IN MIGRAINE PROPHYLAXIS | 4CPS-199 |
| EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE | 4CPS-200 |
| Audit on the prescription and administration of Parkinson’s Disease medication on admission to hospital | 4CPS-201 |
| OPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES | 4CPS-202 |
| COMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS | 4CPS-203 |
| AN EXPLORATION OF PATIENTS’ PERCEPTIONS OF COLORECTAL CANCER AND ITS MANAGEMENT: A QUALITATIVE STUDY AT INITIATION OF TREATMENT WITH CHEMOTHERAPY | 4CPS-204 |
| RIBOCICLIB AS FIRST LINE FOR METASTASIC BREAST CANCER: ANALISIS OF USE AND SECURITY | 4CPS-206 |
| IMPROVING THE SAFETY OF PHARMACOTHERAPY IN PAEDIATRIC HAEMATO-ONCOLOGY BY CLINICAL PHARMACY SERVICES | 4CPS-207 |
| Benefit of Medication Reviews by a Renal Pharmacist in the Setting of a Computerized Physician Order Entry System | 4CPS-209 |
| IMPACT OF THE ANTIBIOTIC THERAPY USED DURING THE SARS-COV-2 PANDEMIC ON THE INCIDENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION | 4CPS-210 |
| Reduction of flushing volume and incompatibilities by a clinical pharmacist in a paediatric intensive care unit | 4CPS-211 |
| INSTRUCTIONS GIVEN BY THE ANAESTHETIST ON THE MANAGEMENT OF CHRONIC TREATMENTS PREOPERATIVELY: WHAT DOES THE PATIENT REALLY UNDERSTAND AND RETAIN? AN OBSERVATIONAL STUDY | 4CPS-212 |
| A COMPARATIVE RISK ANALYSIS COMPARING THE CONVENTIONAL AND FULLY AUTOMATED MANAGEMENT OF CLINICAL TRIALS IN AN ONCOLOGY PHARMACY | 4CPS-213 |
| EXPERIENCE OF USE OF CANNABIDIOL IN PAEDIATRIC PATIENTS | 4CPS-214 |
| PERSISTENCE AND THERAPEUTIC ADHERENCE TO FIRST GENERATION JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS | 4CPS-215 |
| CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACT OF PHARMACISTS’ INTERVENTIONS IN ONCOLOGICAL CARE PATIENTS | 4CPS-217 |
| EVALUATION OF THE IMPACT OF INCORPORATING A PHARMACIST INTO A HOSPITAL EMERGENCY DEPARTMENT | 4CPS-218 |
| POTENTIALLY INAPPROPRIATE MEDICINES IN OLDER PATIENTS | 4CPS-221 |
| ADHERENCE IN POLYMEDICATED ELDERLY PATIENTS ADMITTED TO A TRAUMA WARD | 4CPS-222 |
| ADHERENCE TO ABIRATERONE AND CORTICOID IN PATIENTS WITH PROSTATE CANCER | 4CPS-223 |
| IMPACT OF PROACTIVE MEDICATION RECONCILIATION PRIOR TO PRE-ANAESTHESIC CONSULTATION | 4CPS-224 |
| Integration of a clinical pharmacist in a therapeutic education team for diabetic patients: an initiative that is worth gold! | 4CPS-225 |
| THE ROLE OF THE CLINICAL PHARMACIST IN THE SCREENING OF CANDIDATES FOR ONCOHAEMATOLOGICAL CLINICAL TRIALS | 4CPS-226 |
| Feedback from a French region on the use of e – Therapeutic Patient Education during the health crisis: high-speed interviews! | 4CPS-227 |
| Implementation of an interprofessional pre-operative medication management program in cardiac surgery – a pre post quality improvement study | 4CPS-229 |
| ARE WE SUSTAINABLE? A BASELINE QUESTIONNAIRE REGARDING THE ENVIRONMENTAL IMPACT OF PHARMACY PRACTICE ACROSS THE COUNTRY | 4CPS-231 |
| Pharmacist-led medication review unveiled more medication-related problems in possibly medication-related hospitalisations than in unlikely medication-related hospitalisations in elderly patients | 4CPS-232 | |
| THERAPEUTIC SWITCH OF ANTIRETROVIRAL TREATMENTS: EFFICACY, TOLERABILITY AND REASON FOR CHANGE | 4CPS-233 |
| IMPACT OF AN INTENSIVE MONITORING PROGRAM ON METHOTREXATE ELIMINATION | 4CPS-234 |
| PROFILE OF USE OF PHARMACOTHERAPY IN PSORIASIS, BIOLOGICAL DRUGS AND BIOSIMILARS | 4CPS-235 |
| MEASURING ADHERENCE TO ANTIRETROVIRAL TREATMENT: CORRELATION AND CONCORDANCE BETWEEN TWO INDIRECT METHODS | 4CPS-237 |
| IMPACT OF KNOWLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION ON THE QUALIY OF LIFE OF PEOPLE LIVING WITH HIV | 4CPS-239 |
| DEVELOPMENT OF A 25% BENZYL BENZOATE LOTION FOR A CASE OF RESISTANT NORWEGIAN SCABIES | 4CPS-240 |
| Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine and Bictegravir in a Real-Life Cohort of HIV-Infected Adults | 4CPS-241 |
| HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: ANALYSIS, FOLLOW-UP AND PANDEMIC EFFECT | 4CPS-242 |
| INFLUENCE OF VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION ON THE PHARMACOKINETICS OF VANCOMYCIN IN ADULTS: CAN AN OPTIMAL PHARMACODYNAMIC TARGET BE ACHIEVED? | 4CPS-243 |
| CARDIOVASCULAR, RENAL AND BONE EVALUATION OF A HIV POPULATION OVER 60 YEARS OLD | 4CPS-244 |
| INAPPROPRIATE ANTIBIOTIC DOSAGE ADJUSTMENTS IN PATIENTS WITH RENAL IMPAIRMENT: A CROSS-SECTIONAL ANALYSIS | 4CPS-245 |
| MEDICATION-RELATED ADMISSION WAS MORE FREQUENT IN ELDERLY PATIENTS HOSPITALISED IN AN ORTHOPEDIC UNIT THAN IN AN EMERGENCY DEPARTMENT IN TWO FRENCH HOSPITALS | 4CPS-246 |
| EVALUATION OF THE CLINICAL IMPACT OF MEDICATION RECONCILIATION ON ADMISSION USING THE CLEO TOOL | 4CPS-247 |
| ELTROMBOPAG FOR TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA ASSOCIATED WITH COVID-19 VACCINE: A CASE REPORT | 4CPS-249 |
| HOME DELIVERY FOR OUTPATIENTS WITH IMMUNEMEDIATED DISEASES: EXPERIENCE AND PATIENT SATISFACTION | 4CPS-250 |
| INFLUENCE OF POLYPHARMACY AND COMORBIDITIES IN THE QUALITY OF LIFE OF PATIENTS WHO SUFFER HIP FRACTURE | 4CPS-251 |
| ORAL AND INTRAVENOUS IRON IN THE TREATMENT OF PERIOPERATIVE ANAEMIA | 4CPS-252 |
| DIFFERENCES BETWEEN PHARMACEUTICAL INTERVENTIONS PERFORMED ON ANTIMICROBIALS IN MEDICAL AND SURGICAL SERVICES | 4CPS-253 |
| EFFECTIVENESS AND SAFETY OF NINTEDANIB AND PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 4CPS-257 |
| ACTIVATION, ADHERENCE AND HEALTH OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH BIOLOGICAL DRUGS | 4CPS-258 |
| ANALYSIS OF THE ANTICHOLINERGIC LOAD IN POLYMEDICATED ELDERLY PATIENTS WHO HAVE SUFFERED A FALL | 4CPS-259 |
| PERSISTENCE AND SAFETY OF CALCITONIN GENERELATED PEPTIDE INHIBITORS IN CHRONIC MIGRAINE | 4CPS-260 |
| EVALUATION OF DRY EYE SEVERITY AND THERAPEUTIC ADHERENCE OF PATIENTS ON AUTOLOGOUS SERUM EYE DROPS | 4CPS-262 |
| EVALUATION OF THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS TOCILIZUMAB | 4CPS-263 |
| ANALYSIS OF MEDICAL TREATMENT, RISK FACTORS AND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE NOSOCOMIAL DIARRHOEA | 4CPS-264 |
| CHRONIC COMPLEX PALLIATIVE PAEDIATRIC PATIENT AT-HOME CARE UNIT: PHARMACOTHERAPEUTIC PROFILE AND ANALYSIS OF SIALORRHEA TREATMENT | 4CPS-265 |
| Detection and follow-up of drug related problems for patients with cardiovascular disease: A study of the Medicine Start Service in hospital pharmacies | 4CPS-266 |
| Design, implementation, and evaluation of a medication counselling service provided by pharmacists using teach-back at hospital discharge | 4CPS-267 |
| ANALYSIS OF RECURRENCES AND RISK FACTORS IN INFECTION BY CLOSTRIDIUM DIFFICILE | 4CPS-269 |
| Investigating the Use of Patient Frailty to Guide Pharmacist-led Medication Review | 4CPS-270 |
| ADHERENCE TO MEPOLIZUMAB AND BENRALIZUMAB IN REAL CLINICAL PRACTICE | 4CPS-271 |
| INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY DYSPHAGIA SCREENING TEAM IN AN INTERMEDIATE AND LONG STAY HOSPITAL | 4CPS-272 |
| IMPACT OF A SPECIALIST PHARMACIST ON HEPATOPANCREATICO-BILIARY (HPB) SURGICAL WARD ROUNDS AT A LARGE TERTIARY LIVER CENTRE | 4CPS-273 |
| Evaluation of pharmaceutical interventions documented by a pharmacy technician: Where do pharmacy technicians have the biggest impact to avoid drug-related problems? | 4CPS-274 |
| ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMA | ACPS-189 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS | 5PSQ-002 |
| DEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY | 5PSQ-003 |
| ANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS | 5PSQ-004 |
| DOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY | 5PSQ-006 |
| ASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL | 5PSQ-008 |
| Patient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study | 5PSQ-009 |
| Identification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety | 5PSQ-010 |
| INTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE | 5PSQ-011 |
| ARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION? | 5PSQ-012 |
| ANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS | 5PSQ-013 |
| SAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB | 5PSQ-014 |
| ANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES | 5PSQ-015 |
| ACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE? | 5PSQ-016 |
| MAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY | 5PSQ-017 |
| ANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA | 5PSQ-018 |
| ASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-2 | 5PSQ-019 |
| Patient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden | 5PSQ-021 |
| DESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT | 5PSQ-022 |
| Neutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer | 5PSQ-023 |
| Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC) | 5PSQ-024 |
| ANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV | 5PSQ-025 |
| CLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS | 5PSQ-026 |
| Misuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units | 5PSQ-027 |
| ASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT | 5PSQ-028 |
| EVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE | 5PSQ-029 |
| USE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS | 5PSQ-030 |
| EVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM | 5PSQ-031 |
| COMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING | 5PSQ-032 |
| Positive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany | 5PSQ-033 |
| HOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS | 5PSQ-034 |
| INTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD” | 5PSQ-035 |
| IMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY | 5PSQ-036 |
| DEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE | 5PSQ-038 |
| PHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW | 5PSQ-040 |
| SAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW | 5PSQ-041 |
| TOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS | 5PSQ-042 |
| BENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL | 5PSQ-043 |
| CONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT | 5PSQ-044 |
| ANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL | 5PSQ-045 |
| IMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL | 5PSQ-046 |
| ANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY | 5PSQ-048 |
| STARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT | 5PSQ-049 |
| COST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION | 5PSQ-051 |
| INFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY | 5PSQ-053 |
| ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION | 5PSQ-054 |
| LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT | 5PSQ-055 |
| LOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY | 5PSQ-056 |
| ACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING | 5PSQ-057 |
| EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS | 5PSQ-058 |
| CHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL | 5PSQ-059 |
| LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE | 5PSQ-060 |
| REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS | 5PSQ-062 |
| PERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA | 5PSQ-063 |
| INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS | 5PSQ-065 |
| PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME | 5PSQ-066 | |
| ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE | 5PSQ-067 | |
| INCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA | 5PSQ-068 |
| DOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS? | 5PSQ-069 |
| USEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION | 5PSQ-070 |
| REAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS | 5PSQ-071 |
| COVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE | 5PSQ-074 |
| EVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION | 5PSQ-076 |
| BEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY | 5PSQ-077 |
| THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA | 5PSQ-078 |
| ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING | 5PSQ-080 |
| IMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME | 5PSQ-081 |
| EFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS | 5PSQ-082 |
| USE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT | 5PSQ-083 |
| HOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS | 5PSQ-084 |
| REAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER | 5PSQ-085 |
| EVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION | 5PSQ-086 |
| LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES | 5PSQ-087 |
| ANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE | 5PSQ-088 |
| USE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE | 5PSQ-090 |
| DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS | 5PSQ-091 |
| TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB | 5PSQ-092 |
| PERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS | 5PSQ-093 |
| REASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS | 5PSQ-094 |
| COMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE | 5PSQ-095 |
| USE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS | 5PSQ-097 |
| EXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | 5PSQ-098 |
| MEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL | 5PSQ-101 |
| DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS | 5PSQ-103 |
| VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC | 5PSQ-104 |
| INSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST? | 5PSQ-105 |
| IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM | 5PSQ-106 |
| SECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING | 5PSQ-107 |
| SECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE | 5PSQ-108 |
| OMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE | 5PSQ-110 |
| PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS | 5PSQ-111 |
| HIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS | 5PSQ-112 |
| ANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING | 5PSQ-115 |
| Medication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review | 5PSQ-116 |
| DETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT | 5PSQ-117 |
| LITHIUM THERAPY ON HOSPITAL ADMISSION | 5PSQ-118 |
| IMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE | 5PSQ-120 |
| IMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT | 5PSQ-121 |
| EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION | 5PSQ-122 |
| ORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE? | 5PSQ-123 |
| THE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT | 5PSQ-124 |
| THE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA | 5PSQ-125 |
| CLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT | 5PSQ-128 |
| DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME | 5PSQ-130 |
| PARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS | 5PSQ-131 |
| ANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL | 5PSQ-132 |
| ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER | 5PSQ-133 |
| PATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL | 5PSQ-134 |
| NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK | 5PSQ-135 |
| MEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM | 5PSQ-137 |
| IMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS | 5PSQ-138 |
| ANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS | 5PSQ-139 |
| PATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT | 5PSQ-140 |
| Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations | 5PSQ-141 |
| Development and validation of clinical rules to address risk prescriptions | 5PSQ-144 | |
| MEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION | 5PSQ-145 |
| RISK MAPPING OF DRUG MANAGEMENT IN A PRISON | 5PSQ-146 |
| A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY | 5PSQ-147 |
| TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS | 5PSQ-148 | |
| DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE | 5PSQ-149 | |
| Implementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital | 5PSQ-150 |
| OPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB | 5PSQ-151 |
| EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS | 5PSQ-152 |
| PERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES | 5PSQ-153 |
| Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance | 5PSQ-154 |
| HOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL? | 5PSQ-155 |
| REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION | 5PSQ-156 |
| SEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES | 5PSQ-157 |
| Food and drink management as part of medicaton administration safety | 5PSQ-158 |
| PDF Document | Poster Title | Poster Number |
|---|---|---|
| ADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS | 5PSQ-002 |
| DEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY | 5PSQ-003 |
| ANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS | 5PSQ-004 |
| DOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY | 5PSQ-006 |
| ASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL | 5PSQ-008 |
| Patient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study | 5PSQ-009 |
| Identification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety | 5PSQ-010 |
| INTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE | 5PSQ-011 |
| ARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION? | 5PSQ-012 |
| ANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS | 5PSQ-013 |
| SAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB | 5PSQ-014 |
| ANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES | 5PSQ-015 |
| ACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE? | 5PSQ-016 |
| MAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY | 5PSQ-017 |
| ANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA | 5PSQ-018 |
| ASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-2 | 5PSQ-019 |
| Patient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden | 5PSQ-021 |
| DESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT | 5PSQ-022 |
| Neutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer | 5PSQ-023 |
| Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC) | 5PSQ-024 |
| ANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV | 5PSQ-025 |
| CLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS | 5PSQ-026 |
| Misuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units | 5PSQ-027 |
| ASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT | 5PSQ-028 |
| EVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE | 5PSQ-029 |
| USE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS | 5PSQ-030 |
| EVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM | 5PSQ-031 |
| COMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING | 5PSQ-032 |
| Positive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany | 5PSQ-033 |
| HOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS | 5PSQ-034 |
| INTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD” | 5PSQ-035 |
| IMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY | 5PSQ-036 |
| DEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE | 5PSQ-038 |
| PHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW | 5PSQ-040 |
| SAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW | 5PSQ-041 |
| TOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS | 5PSQ-042 |
| BENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL | 5PSQ-043 |
| CONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT | 5PSQ-044 |
| ANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL | 5PSQ-045 |
| IMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL | 5PSQ-046 |
| ANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY | 5PSQ-048 |
| STARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT | 5PSQ-049 |
| COST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION | 5PSQ-051 |
| INFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY | 5PSQ-053 |
| ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION | 5PSQ-054 |
| LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT | 5PSQ-055 |
| LOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY | 5PSQ-056 |
| ACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING | 5PSQ-057 |
| EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS | 5PSQ-058 |
| CHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL | 5PSQ-059 |
| LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE | 5PSQ-060 |
| REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS | 5PSQ-062 |
| PERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA | 5PSQ-063 |
| INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS | 5PSQ-065 |
| PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME | 5PSQ-066 | |
| ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE | 5PSQ-067 | |
| INCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA | 5PSQ-068 |
| DOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS? | 5PSQ-069 |
| USEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION | 5PSQ-070 |
| REAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS | 5PSQ-071 |
| COVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE | 5PSQ-074 |
| EVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION | 5PSQ-076 |
| BEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY | 5PSQ-077 |
| THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA | 5PSQ-078 |
| ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING | 5PSQ-080 |
| IMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME | 5PSQ-081 |
| EFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS | 5PSQ-082 |
| USE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT | 5PSQ-083 |
| HOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS | 5PSQ-084 |
| REAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER | 5PSQ-085 |
| EVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION | 5PSQ-086 |
| LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES | 5PSQ-087 |
| ANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE | 5PSQ-088 |
| USE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE | 5PSQ-090 |
| DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS | 5PSQ-091 |
| TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB | 5PSQ-092 |
| PERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS | 5PSQ-093 |
| REASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS | 5PSQ-094 |
| COMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE | 5PSQ-095 |
| USE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS | 5PSQ-097 |
| EXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | 5PSQ-098 |
| MEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL | 5PSQ-101 |
| DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS | 5PSQ-103 |
| VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC | 5PSQ-104 |
| INSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST? | 5PSQ-105 |
| IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM | 5PSQ-106 |
| SECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING | 5PSQ-107 |
| SECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE | 5PSQ-108 |
| OMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE | 5PSQ-110 |
| PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS | 5PSQ-111 |
| HIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS | 5PSQ-112 |
| ANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING | 5PSQ-115 |
| Medication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review | 5PSQ-116 |
| DETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT | 5PSQ-117 |
| LITHIUM THERAPY ON HOSPITAL ADMISSION | 5PSQ-118 |
| IMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE | 5PSQ-120 |
| IMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT | 5PSQ-121 |
| EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION | 5PSQ-122 |
| ORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE? | 5PSQ-123 |
| THE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT | 5PSQ-124 |
| THE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA | 5PSQ-125 |
| CLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT | 5PSQ-128 |
| DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME | 5PSQ-130 |
| PARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS | 5PSQ-131 |
| ANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL | 5PSQ-132 |
| ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER | 5PSQ-133 |
| PATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL | 5PSQ-134 |
| NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK | 5PSQ-135 |
| MEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM | 5PSQ-137 |
| IMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS | 5PSQ-138 |
| ANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS | 5PSQ-139 |
| PATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT | 5PSQ-140 |
| Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations | 5PSQ-141 |
| Development and validation of clinical rules to address risk prescriptions | 5PSQ-144 | |
| MEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION | 5PSQ-145 |
| RISK MAPPING OF DRUG MANAGEMENT IN A PRISON | 5PSQ-146 |
| A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY | 5PSQ-147 |
| TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS | 5PSQ-148 | |
| DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE | 5PSQ-149 | |
| Implementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital | 5PSQ-150 |
| OPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB | 5PSQ-151 |
| EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS | 5PSQ-152 |
| PERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES | 5PSQ-153 |
| Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance | 5PSQ-154 |
| HOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL? | 5PSQ-155 |
| REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION | 5PSQ-156 |
| SEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES | 5PSQ-157 |
| Food and drink management as part of medicaton administration safety | 5PSQ-158 |
